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Abstract 
 
Melanocytic naevi (or naevi) are benign melanocytic proliferations, although studies have shown 
that the number of naevi and/or presence of clinically atypical naevi on an individual are strong 
predictors of risk for cutaneous melanoma. Melanomas may grow adjacent to or within naevi and 
naevi commonly harbour the same somatic mutations implicated in melanoma development. As 
naevi are intermediate markers of melanoma risk, understanding of their clinical and molecular 
biology has implications for melanoma treatment and prevention. Dermoscopy is a widely used 
clinical examination technique that allows visualisation of skin lesions through magnification of the 
skin surface and subsurface architecture not visible to the naked eye. Distinct subsets of acquired 
naevi with unique dermoscopic patterns, corresponding to microanatomical growth patterns, are 
distinguished by their age of onset, life cycle and relative melanoma risks. Prior to this study, the 
BRAF mutation had been detected in acquired naevi with the globular, reticular and peripheral rim 
of globules pattern using a variety of methodologies with dissimilar results for reticular naevi. 
Despite the role of dermoscopy as the clinico-pathologic interface, the genetic landscape of these 
dermoscopic subsets of acquired naevi remained to be fully elucidated.  
 
Highly sensitive methodologies (droplet digitalTM PCR or ddPCR) and a comprehensive discovery 
approach (whole exome sequencing or WES) were used to investigate the somatic mutational 
landscape present within prospectively recruited acquired naevi with the globular, reticular, and 
peripheral rim of globules dermoscopic patterns. Where possible, matching naevi and adjacent non-
lesional skin were also cultured to enable future functional assessment.  
 
Firstly, using ddPCR, this study discovered that 100% of globular, reticular and peripheral rim of 
globules dermoscopic subtypes of acquired naevi had mutually exclusive BRAF or NRAS mutations. 
BRAF mutations were present in all three dermoscopic naevus subsets whereas NRAS mutations 
were more likely to be present in reticular naevi. Next, to discover the underlying molecular 
mechanisms involved in naevogenesis, somatic WES that was used to assess the naevi and 
matching adjacent non-lesional skin confirmed the presence of BRAF and NRAS mutations, together 
with a wide range of somatic mutations (30-668 mutations) or 0-9 mutations per megabase.  C>T 
transitions were confirmed to be the most prevalent single-nucleotide variant class and overall the 
analysed naevi share many similarities to the mutation frequency distribution in cutaneous 
melanoma. Notably, there was a prevalent proportion of ultraviolet radiation-related (97%), age-
related (93%) and defective DNA repair-related signatures (30%). Based upon these findings, this 
study has identified some novel mechanisms which contribute to naevogenesis. 
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In relation to dermoscopic patterns, mutational signature analysis identified globular naevi to have a 
significantly higher proportion of T[C>T]A transitions; but overall globular naevi are largely 
genomically silent containing only minor copy number aberrations (CNAs). Reticular naevi and 
naevi with a peripheral rim of globules were more likely to have a higher proportion of indels and 
genome-wide CNAs. The majority of the observed CNAs were large regional loss-of-
heterozygosity events rather than focal regions of loss. The CNAs involving key melanoma-related 
genes located in these regions of loss are both tumour suppressors and oncogenes. Thus it is likely 
that the net effect from the loss of both gene functions in naevi have an overall copy neutral effect, 
keeping naevi in a state of equilibrium and in part help to explain the low overall transformation 
rate of an individual naevus. 
 
Lastly, globular naevi did not propagate in culture experiments. This is postulated to be due to a 
higher BRAF V600E fractional abundance causing oncogene-induced senescence. In cultured 
naevocytes derived from BRAF mutant reticular naevi and naevi with a peripheral rim of globules, 
there is evidence for intratumoral heterogeneity and polyclonal cell populations based upon WES 
and comparisons with matching tissue. 
 
This thesis has contributed to the clinico-dermoscopic-pathologic-genomic correlation of acquired 
naevi with the globular, reticular and peripheral rim of globules dermoscopic patterns. The somatic 
mutational landscape of these dermoscopic naevus subsets provides an insight into naevogenesis 
and distinguishes some of the molecular hallmarks of naevi in relation to melanoma. Overall, the 
findings discussed in this thesis support the role of the mitogen-activated protein kinase (MAPK) 
pathway in the development of benign melanocytic proliferations and provide evidence that the 
maintenance of naevi in a state of equilibrium is an interplay between various genomic factors.  
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CHAPTER 1 
Introduction 
1.1 BACKGROUND  
It is well established that individuals at risk of cutaneous melanoma have high naevus counts 
(pooled relative risk = 1.47 for 16-40 naevi and 6.89 for 101-120 naevi compared to 0-15 naevi)1 or 
melanocytic naevi with atypical clinical features1-5. A specific phenotype known as atypical naevus 
syndrome, diagnosed based on a scoring system developed by Bishop et al6,7 also has the ability to 
characterise families at risk of melanoma6,8. As naevi have been shown to co-exist in 
histopathologic contiguity with cutaneous melanoma, these melanocytic proliferations have also 
been postulated to be the pre-malignant and direct precursor to melanoma9.  
In the clinic, dermoscopy (dermatoscopy, epiluminescence microscopy or skin surface microscopy) 
is a bedside examination technique that has improved the diagnostic accuracy of malignant skin 
tumours such as melanoma with a higher discriminatory power than naked-eye examination10-17. It 
is a non-invasive and in vivo surface microscope technique that utilises an incident light 
magnification system with or without immersion fluid. This technique today involves viewing skin 
lesions using a hand-held device usually with a 10-fold magnification lens called a dermatoscope 
(dermoscope), or a video imaging system applied to the skin. The surface reflection renders the 
stratum corneum to be translucent and enables visualisation of skin surface and subsurface 
anatomical structures at the level of the epidermis, dermo-epidermal junction (DEJ) and superficial 
papillary dermis, not visible to the naked eye.  
In the evaluation of melanocytic proliferations, dermoscopy has unveiled a new dimension in the 
clinical assessment allowing for a more detailed observation of colour and structure12. Studies to 
date demonstrate that morphological features and criteria seen using dermoscopy correlate well 
with histopathological substrates, and therefore considered to be an in vivo representation of gross 
pathology13-16,18. The differentiation of naevi from melanoma using dermoscopy is achieved using 
diagnostic algorithms with specific dermoscopic criteria10-13,19-21, consequently reducing the number 
of excisions of naevi17.  
Moreover, dermoscopy facilitates sequential monitoring of melanocytic proliferations with the 
feasibility of acquiring, storing and retrieving digitalised dermoscopic images. This has enabled 
clinicians to monitor the morphology of individual melanocytic proliferations to detect any 
melanoma-specific changes over time22, and as a consequence melanoma detection is improved in 
individuals with clinically atypical melanocytic proliferations and/or high naevus counts. This 
possibility of longitudinal follow-up has also provided the means to further understand and study 
the epidemiology, morphology and evolutionary life cycle of naevi. 
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However, although dermoscopy has been able to bridge the clinico-pathologic interface in the 
diagnosis of melanocytic proliferations, diagnosis of a malignancy based on morphologic criteria 
alone has limitations as naevi and melanoma share overlapping phenotypic features. As we embark 
into the molecular era, it has become feasible to explore the link between naevi and melanoma in a 
new dimension that will provide additional insight into their morphology and biology. In particular, 
knowledge on the genetic properties of naevi underpinning their phenotypic characteristics and 
evolution may inform our understanding of the pathways leading to cutaneous melanoma.  
This study is part of a vision that aims to identify the molecular hallmarks of naevi in relation to 
melanoma. The goal is to identify somatically acquired mutations, rare variants or mutational 
signatures to further understand the molecular mechanisms of naevogenesis that may lead to 
melanomagenesis, as well as to validate or identify distinct dermoscopic naevus subsets based on 
genotypic data. As dermoscopy provides the bridge between clinical and histopathologic criteria, 
this phenotypic-genotypic study of naevi has been stratified according to dermoscopic pattern to 
also facilitate the translation of study results into future clinical practice.  
1.2 CLASSIFICATION OF MELANOCYTIC NAEVI  
1.2.1 Clinical history 
The traditionally used classification scheme is based on clinical history and divides naevi into 
congenital or acquired depending on time of onset. 
Congenital melanocytic naevi 
By definition, congenital melanocytic naevi (CMN) develop in utero and are present at birth and are 
classed as small (< 1.5cm), medium (1.5-10cm), large (11-20cm), and giant (≥20cm), with the 
larger CMN conferring greater potential for melanoma development23. Somatic mutations in NRAS 
has been linked with CMN, with a higher prevalence of NRAS mutations in large and giant CMN as 
compared to small and medium CMN (94.7% vs 70% respectively)24. 30% of small to medium 
CMN harbour the BRAF mutation24. 
Some small naevi (< 10mm in diameter) display histopathological features found in naevi present at 
birth that are typified by large, predominantly intradermal nests often with a periadnexal 
distribution; but lack the definitive history of presence at birth. As these develop during early 
childhood rather than in utero, they have been referred to as congenital pattern naevi, congenital 
naevus-like naevi, or ‘tardive’ CMN to reflect their overlapping similarities to ‘true’ CMN25. In 
order to indicate its onset more accurately, these naevi have also occasionally been labelled as 
early-acquired melanocytic naevi (early AMN). Bauer et al demonstrated differences between ‘true’ 
CMN and congenital pattern naevi26. 71% of congenital pattern naevi harbour the BRAF mutation, 
contrary to 81% of ‘true’ CMN without the BRAF mutation (harbour the NRAS mutation instead)26. 
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Therefore histopathologic criteria alone is unable to reliably distinguish between small ‘true’ CMN 
and congenital pattern naevi. 
Acquired melanocytic naevi 
Acquired melanocytic naevi (AMN) develop after birth and constitute the most common naevi. 
These naevi may be clinically typical in appearance (‘common’ or ‘ordinary’ naevi) or clinically 
atypical, but it is important to note they are essentially benign melanocytic proliferations. In 1990, 
Ackerman and Magana-Garcia acknowledged the disagreement amongst dermatologists and 
pathologists in the classification of melanocytic proliferations and in the nomenclature surrounding 
naevi27. As a first step towards an integrated approach, Ackerman and Magana-Garcia made a 
proposal for the eponymously named Unna’s naevus, Miescher’s naevus, Clark’s naevus and 
Spitz’s naevus; recognised based on gross clinical appearance, distinct histopathology silhouette 
and biology, in honour of the individuals who first recognised or popularised these AMN27. As 
opposed to CMN where size is the determinant of malignancy risk, the number of AMN has been 
found to be the strongest predictor of melanoma risk, with the risk of de novo development of 
melanoma increasing almost linearly with naevus counts26. The number of clinically atypical AMN 
(Clark/dysplastic naevi) is also a considerable independent risk factor for melanoma in the general 
population, especially in individuals with the aforementioned atypical naevus syndrome28. A high 
frequency of BRAF mutation has been detected in Clark/dysplastic naevi29 and in several AMN 
dermoscopic subtypes30,31 (details under “Dermoscopic-molecular correlation of melanocytic naevi” 
section below). 
1.2.2 Histopathologic criteria  
Histopathologic classification of naevi is dependent on the anatomic location of 
melanocytes/naevocytes/naevomelanocytes (melanin-producing cells) within the layers of the skin, 
subcategorising naevi into three types: (1) junctional naevus (Figure 1a) that consists of discrete 
nests of naevocytes at the DEJ layer of the epidermis, particularly at the rete ridges 
(intraepidermal); (2) dermal naevus (Figure 1c) that is composed of naevocytes confined wholly to 
the dermis, arranged in nests and cords (intradermal); and (3) compound naevus (Figure 1b) that 
consists of nests of naevocytes at both the DEJ and within the dermis (both intraepidermal and 
intradermal). Histopathology is regarded as the ’gold’ standard in the diagnosis of melanocytic 
proliferations, but it is only able to provide a cross-sectional view in the life of any given individual 
naevus. 
 22 
 
 
1.2.3 Dermoscopic pattern  
The dermoscopic assessment of naevi is dependent on (1) colour, (2) pattern, (3) pigment 
distribution and (4) body-site specific pattern. Colour can be observed as black, brown, grey and 
blue under the dermatoscope according to the location of melanin-containing melanocytes, 
keratinocytes or melanophages in the different skin layers (Table 1). Pattern can be perceived as 
globular, reticular, starburst, structureless/homogeneous and mixed. Pigment may be distributed in a 
uniform, central, eccentric and multifocal manner. Naevi on special sites such as face, acral sites 
and nail have been observed to have site-specific patterns. 
Dermoscopic pattern, an in vivo representation of gross pathology, provides a clinico-pathologic 
classification approach towards naevi. The Memorial Sloan-Kettering Cancer Centre (MSKCC; 
New York, U.S.A.) adapted a dermoscopic pattern classification for naevi based on observations 
outlined by Hoffman-Wellenhof et al for clinically atypical naevi32. Accordingly, the existence of 
four dermoscopic pattern groups: (1) globular pattern, (2) reticular pattern, (3) 
structureless/homogeneous brown pattern, and (4) reticuloglobular pattern; have been used as the 
foundation for their published work33-35.  
 
Figure 1. Histopathologic 
classification of naevi. (a) 
junctional naevus – consists of 
discrete nests of naevocytes at the 
DEJ layer of the epidermis, 
particularly at the rete ridges, (b) 
compound naevus - consists of 
nests of naevocytes at both the 
DEJ and within the dermis, and 
(c) dermal naevus - composed of 
naevocytes confined wholly to 
the dermis, arranged in nests and 
cords. 
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Table 1. Dermoscopic colours and their histopathologic correlates.  
Colour Histopathologic Correlate Skin Anatomic Level 
Black Melanin either in keratinocytes or melanocytes Stratum corneum 
Brown Melanin either in keratinocytes or melanocytes DEJ 
Grey Melanin either in melanocytes or melanophages Superficial papillary dermis 
Blue Melanin either in melanocytes or melanophages Papillary or reticular dermis 
 
In the second approach by Zalaudek et al, AMN and ‘tardive’ CMN/early AMN are distinguished 
based on five dermoscopic patterns: (1) globular, (2) reticular, (3) mixed pattern with central 
structureless brown-grey area/network surrounded by a peripheral rim of small brown globules, (4) 
mixed pattern with central globules/structureless area surrounded by a peripheral network, and (5) 
unspecified pattern36. Notably some of these observed patterns may not represent distinct 
dermoscopic naevus subgroups. For example, as longitudinal data has observed the 
structureless/homogeneous brown pattern to change to or from either reticular or globular pattern33, 
it is likely to represent a heterogeneous group of naevi37. Moreover these naevi can be 
histopathologically junctional or compound naevi, therefore demonstrate overlapping 
histopathologic features with dermoscopically globular and reticular naevi32. It is also yet to be 
determined if mixed pattern naevi represent a distinct entity, or belong to globular or reticular naevi 
from a clinico-pathologic perspective37. However, mixed pattern naevi with a peripheral rim of 
globules (PG) potentially constitute a unique subset due to its growth dynamics.  
To add another layer of complexity, more recently, Argenziano et al proposed a new classification 
scheme dividing the most common naevi encountered in clinical practice (<15mm in diameter) into 
seven groups: (1) globular “congenital” naevus, (2) reticular “acquired” naevus, (3) starburst 
“Spitz/Reed” naevus, (4) blue “homogeneous” naevus, (5) site-related naevi, (6) naevi with special 
features and (7) unclassifiable melanocytic lesions38. The first four types of naevi were categorised 
based on common epidemiologic and morphologic features with distinct clinico-pathologic 
correlation. The latter three groups differ from the former four groups as these naevi either have 
site-specific features, or unusual clinical features which have potentially conflicting diagnostic 
criteria from a clinico-pathologic and/or histopathologic standpoint.  
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1.3 THEORIES OF NAEVOGENESIS  
1.3.1 Unidirectional melanocyte migration 
Unna’s downward migration “Abtropfung” theory  
In 1893, Paul Gerson Unna introduced the concept of naevocytes developing and proliferating from 
within the epidermis, then migrating downwards via the DEJ and into the dermis over time25. 
Unna’s theory therefore implies that naevi are first junctional in nature, then compound as it 
consists of both junctional and dermal components, and finally the naevocytes complete the 
migration into the dermis to become dermal naevi. Dermoscopically this movement of melanocytes 
from the epidermis to the dermis corresponds to reticular naevi in youth progressively becoming 
globular naevi later in life. However, the observed age-dependant shift from globular (81% in 
individuals <15 years of age) to reticular naevi (69% in individuals >60 years of age) in a cross-
sectional dermoscopic study39 seem to challenge Unna’s theory, but favour Cramer’s upward 
migration theory described below.  
Cramer’s upward migration “Hochsteigerung” theory 
In 1984, Cramer challenged Unna’s theory based on new knowledge that melanocytes originated 
from the neural crest and so must ascend along individual nerve fibres through the dermis in an 
upward migration fashion25. Cramer’s theory postulates that naevi start as dermal naevi with the 
globular pattern in youth, then become compound naevi as some of the naevocytes ascend into the 
epidermis, and finally later in life this process would result in junctional naevi with the reticular 
pattern when there are no residual melanocytes in the dermis.  
Dispute towards the concept of unidirectional melanocyte migration  
Longitudinal dermoscopic data from a population-based study of 366 adolescent children observed 
stability in the dermoscopic patterns of individual naevi, where globular and reticular naevi in 
particular did not seem to cross over in pattern33. The stability of dermoscopic pattern during the 
life cycle of a naevus33 disputes both Unna’s and Cramer’s unidirectional melanocyte migration 
theories. 
1.3.2 The dual pathway of naevogenesis 
Zalaudek et al proposed the dual pathway of naevogenesis40 in 2007 based on dermoscopic 
observations that globular and reticular pattern naevi demonstrate age-related prevalence39. This 
alternative concept of naevus development also suggests that most naevi retain their original 
dermoscopic pattern throughout the life of the naevus, and encompasses (1) the constitutive or 
endogenous pathway for globular naevi and (2) the acquired or exogenous pathway for reticular 
naevi.  
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Constitutive/endogenous pathway – globular pattern  
Globular naevi (Figure 2 a, b, c) are typically either compound or dermal naevi on histopathology 
as the globules correspond to nests of naevocytes at both the DEJ and papillary dermis, or entirely 
in the dermis (Figure 2 d, e). They may demonstrate a congenital pattern on histopathology and 
have been associated with CMN, hence being labelled as ‘tardive’ CMN and referred to as 
“congenital” naevi by Argenziano et al38. Globular naevi are prevalent in childhood36, tend to have 
a stable life cycle and lifelong persistence25,40.  
 
 
Acquired/exogenous pathway - reticular pattern  
Reticular naevi (Figure 3 a, b and c) are usually junctional naevi on histopathology as the pigment 
network corresponds to a lentiginous/single layer of melanin-containing naevocytes and 
keratinocytes along the basal layer of regularly elongated rete ridges of the DEJ or nests of 
naevocytes accumulated at the tips of these elongated rete ridges (Figure 3d). The melanin-rich rete 
ridges appear as pigmented lines and the less pigmented or non-pigmented suprapapillary plates 
appear as holes, conferring the network appearance. Occasionally the naevocytes are present at both 
the DEJ and the dermis on histopathology corresponding to a compound naevus (Figure 3e). 
Figure 2. Globular pattern naevi. These naevi have numerous different sized round to oval 
brown structures on dermoscopy as illustrated in (a), (b) and (c). Histopathologically these are 
compound naevi as the globules correspond to nests of naevocytes at both the DEJ and papillary 
dermis depicted in (d) or nests of naevocytes that are entirely in the dermis as in the 
papillomatous dermal naevus in (e). 
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Reticular naevi have been referred to as acquired naevi, as this dermoscopic naevus type is 
commonly seen in adults39 and has been found to be the pattern demonstrated in 47.1% of new 
naevi developing in adulthood35. Further epidemiologic evidence suggests reticular naevi increase 
in number from puberty until midlife, and then decrease in number later in life as these naevi 
eventually involute25,40,41. 
 
 
Conclusions from the dual pathway of naevogenesis 
The constitutive/endogenous pathway suggests globular naevi develop from dermal naevocytes 
during the pre-pubertal period, then persist, and eventually acquire the stereotypical clinical 
appearance of intradermal naevi (eponymously named Unna or Miescher type) later in life40. 
Conversely, in the acquired/exogenous pathway it is proposed that reticular naevi derive from 
epidermal naevocytes that proliferate at the DEJ (possibly in response to external factors such as 
intermittent ultraviolet exposure) causing an increase in naevus counts from puberty until midlife, 
and then regress later in life40. 
Figure 3. Reticular pattern naevi. These naevi demonstrate a network of pigmented or brown 
interconnected lines on dermoscopy as illustrated in (a), (b) and (c). Histopathologically these 
are either a junctional naevus depicted in (d), where the pigment network corresponds to a 
lentiginous layer of melanin-containing naevocytes and keratinocytes along the basal layer of 
regularly elongated rete ridges of the DEJ or nests of naevocytes accumulated at the tips of these 
elongated rete ridges; or a compound naevus where the naevocytes are present at both the DEJ 
and the dermis (e). 
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This theory of naevogenesis may explain the difference between the cytomorphology of dermal 
melanocytes in nest formation and single junctional melanocytes, as the former which is more 
prevalent in globular naevi usually have oval and medium-sized nuclei whereas the latter 
accounting for reticular naevi are smaller and likely to have irregularly formed nuclei and dendritic 
extensions40. This concept may also explain the risks posed by naevi formed in the individual 
pathways, with reticular naevi being “acquired” through exogenous/external factor(s) and hence an 
indicator for de novo melanoma development; whilst globular naevi are true melanoma precursors40 
consistent with studies reporting melanoma-associated naevi having predominantly “constitutive” 
dermal components42-44.  
1.3.3 A third pathway to naevi?  
Indicator of naevi growth – mixed pattern with a peripheral rim of globules 
Naevi with a peripheral rim of globules (Figure 4a, b, c) may be junctional naevi on histopathology 
(Figure 4d), but are typically compound naevi according to histopathology where there are centrally 
located dermal and epidermal nests of naevocytes and large heavily pigmented junctional nests of 
naevocytes in the periphery (Figure 4e), with the latter feature thought to be the histopathologic 
substrate for the rim of globules45. The differences in the histopathologic substrate between the 
globules that constitute the peripheral rim of globules and the globules of a globular pattern 
papillomatous dermal naevus are that the globules correspond to junctional nests of naevocytes in 
the former (Figure 5a and b) and a cap-like pigmentation of naevocytes in the dermis in the latter 
(Figure 5c and d). Longitudinal dermoscopic studies found that these naevi exhibit symmetrical 
enlargement over time, an implication that growth does not always indicate malignant 
degeneration22,46. Naevi with a peripheral rim of globules constitute 49% of enlarging naevi, with 
the relative risk of enlargement to be 28-fold higher (95% confidence interval) for naevi with a 
peripheral rim of globules than naevi without a peripheral rim of globules45. Further to this, a recent 
study examining the growth pattern of PG naevi reported 96% (n=116) of lesions enlarged at some 
point during sequential monitoring, but these lesions display a decrease in the density of the 
peripheral globules over time46. Once optimal growth has been achieved, PG naevi lose their rim of 
globules as the larger peripheral junctional nests extend horizontally to manifest either a reticular 
pattern (e.g. reticular naevus), or a mixed pattern with central globules/structureless area with a 
peripheral network, followed by involution41. Incidentally, this dermoscopic pattern was not found 
in individuals older than 60 years of age, had an onset during puberty and early adolescence, a peak 
incidence at 11-30 years of age, with the number decreasing rapidly after the third decade of life36. 
Thus, these findings suggest that the transient nature of this dermoscopic pattern is a signature for 
the growth phase of naevi.  
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Figure 4. Mixed pattern naevi with a peripheral rim of globules (PG naevi). 
Dermoscopically these naevi demonstrate a peripheral rim of small brown globules with either a 
central network as illustrated in (a) and (b), or central globules/structureless brown-grey area as 
in (c). Histopathologically PG naevi with a central network are junctional naevi as depicted in 
(d), whereas PG naevi with central globules/structureless areas contain dermal nests that 
predominate at the centre of the lesion as in (e). Both types of PG naevi have large heavily 
pigmented peripheral junctional nests of naevocytes. 
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1.4 DERMOSCOPIC-MOLECULAR CORRELATION OF MELANOCYTIC NAEVI 
Due to the complexity of using history and morphologic criteria to reliably determine which naevi 
are at risk for melanoma, there is a clinically unmet need to identify naevi based on a clinico-
pathologic-molecular approach. The investigation into biological subsets of naevi using the 
dermoscopic classification of naevi provides a correlation with microanatomical growth 
patterns30,31,40, time of onset36,39, life cycle36 and relative melanoma risks36,39,40. To date, somatic 
mutations in HRAS have been linked with Spitz ‘starburst pattern’ naevi whereas GNAQ is 
associated with blue ‘homogeneous blue pattern’ naevi47. It is believed that the benign and stable 
nature of Spitz and blue naevi are likely to be attributed to the non-existence of BRAF and NRAS 
mutations in these naevi types, and alterations in HRAS and GNAQ not being key players in 
melanomagenesis47.  
Further to this, BRAF status was used to molecularly differentiate naevi from various other 
dermoscopic subgroups30,31. In 2011 Zalaudek et al evaluated the frequency of BRAF mutation in 
Figure 5. The histopathologic substrate for globules on dermoscopy. (a) The peripheral rim 
of globules in a mixed pattern naevus with a peripheral rim of globules i.e. PG naevus 
correspond to junctional nests of naevocytes, which are shown at a higher magnification in (b). 
(c) The globules of a globular pattern papillomatous dermal naevus correspond to cap-like 
pigmentation of naevocytes in the dermis, which is demonstrated at a higher magnification in 
(d).  
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four dermoscopic pattern groups consisting of globular (n=5), reticular (n=17), mixed pattern with 
central globules/homogeneous area with a peripheral network (n=12) and mixed pattern 
reticular/homogeneous naevi with a peripheral rim of globules (n=11)30. The authors compared two 
different mutation detection methods (ultradeep pyrosequencing and Sanger sequencing) of 
formalin-fixed paraffin embedded naevi specimens. BRAF mutation was more frequent in globular 
and mixed pattern naevi with a peripheral rim of globules, as well as more recurrent in 
histopathologically diagnosed dermal and compound naevi. The authors were unable to draw 
conclusions for reticular naevi as both sequencing methods revealed discordant results for this 
subtype.  
Likewise, a subsequent study by Marchetti et al looked into BRAF V600E expression in naevi 
using immunohistochemistry, and presented statistically significant findings that BRAF V600E 
expression was detected in 91.7% (n=11/12) of globular naevi and only in 30.1% (n=4/13) of 
reticular naevi31. The authors also investigated the association of BRAF mutation and 
microanatomical growth patterns, assessing formalin-fixed paraffin embedded histopathologic 
sections based on four criteria: (1) junctional, compound or intradermal naevi, (2) the predominant 
microanatomical growth pattern, (3) nest formation of junctional melanocytes, and (4) presence or 
absence of architectural disorder and cytological atypia. Marchetti et al revealed that globular naevi, 
most often corresponding to predominantly dermal growth pattern and/or presence of large 
junctional nests are at least 3 times more likely to harbour BRAF V600E (86.7% vs 20%, p=0.002) 
than reticular naevi, characterised by smaller junctional or compound nests31. Therefore, findings 
from Marchetti et al support the more recent discovery that intradermal naevi are significantly 
(p<0.001) more likely to harbour BRAF mutations than junctional naevi48-50 and conversely BRAF 
V600E positive naevi are less likely to have a junctional component (p=0.04) or show lentiginous 
growth (p=0.023)44.  
In another study on growing melanocytic proliferations, Loewe et al reported that the presence of a 
BRAF V600E mutation was 13 times higher (p<0.001) in growing lesions as compared to lesions 
without changes51. This consisted of 51% (n=25/49) of histopathologically diagnosed naevi 
demonstrating growth, although the dermoscopic pattern and consequently the number of naevi 
with a peripheral rim of globules was not reported by the authors. 
1.5 SOMATIC ALTERATIONS IN MELANOCYTIC PROLIFERATIONS 
1.5.1 Genomic landscape of melanoma 
The genomic landscape of cutaneous melanoma has been studied most extensively and are 
characterised by driver mutations, ultraviolet radiation (UVR) mutational signature, copy number 
aberrations and structural rearrangements52,53. Cutaneous melanomas have been classified into 4 
genomic subtypes based on the pattern of the most prevalent significantly mutated genes: BRAF 
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subtype, RAS family (NRAS/HRAS/KRAS) subtype, NF1 subtype and triple-WT (wild-type) 
subtype52. The BRAF subtype is the largest genomic subtype, followed by RAS, NF1 and triple-WT. 
The triple-WT melanoma subtype is a heterogeneous group characterised by lack of hotspot BRAF, 
RAS or NF1 mutations52.  
In contrast, acral and mucosal melanomas demonstrate a markedly different genomic landscape to 
cutaneous melanoma with a lower mutation burden dominated by large-scale copy number 
aberrations and structural rearrangements53. Acral and mucosal melanomas lacked a UVR 
mutational signature but harboured alternate mutational signatures not previously identified in 
melanoma, including those of unknown aetiology53. Furthermore, 51% of acral and mucosal 
melanomas lacked BRAF, RAS or NF1 mutations (i.e. triple-WT) but harboured loss-of-function 
mutations in other driver genes including CDKN2A, TP53 and ARID2. Notably, GNAQ and SF3B1 
were commonly mutated in uveal and triple-WT mucosal melanomas but not in cutaneous 
melanomas53.  
In sum, the significantly mutated genes include BRAF, CDKN2A, NRAS, TP53, ARID2, CWH43, 
NF1, PTEN and RB1 in cutaneous melanoma; BRAF, KIT, MAP2K2, NF1 and NRAS in acral 
melanoma; and SF3B1 in mucosal melanoma53. 
1.5.2 Mutation burden in melanoma 
The first large high coverage whole genome sequencing study of 183 melanoma samples 
comprising 75 primary melanoma tumours, 93 metastases and 15 cell lines derived from metastases 
that included 140 cutaneous melanomas, 35 acral melanomas and 8 mucosal melanomas identified 
20,894,255 substitutions and 96,467 small insertions and deletions (indels) at an average rate of 
38.23 mutations per megabase53. Cutaneous melanomas had a mean 49.17 mutations per megabase, 
which was >18 times as many mutations than acral and mucosal melanomas (mean 2.64 mutations 
per megabase)53.  
1.5.3 Gene mutations and signalling pathways in melanocytic proliferations 
BRAF (melanoma and naevi) 
The BRAF oncogene on chromosome 7q34 consists of 18 exons and encodes a serine/threonine 
kinase (v-raf murine sarcoma viral oncogene homolog B1) within the mitogen-activated protein 
kinase (MAPK) pathway. Somatic mutations of the BRAF oncogene commonly occur in exons 11 
and 15, and leads to increased cell proliferation and survival due to overactivation of the MAPK 
pathway. The BRAF mutation accounts for 52% of primary and metastatic cutaneous melanomas52 
whereas the majority of acral and mucosal melanomas lacked the BRAF mutation53. Specifically, 
somatic mutations in the V600 codon of BRAF have been detected in 35-50% of melanomas52,54-57, 
most commonly in cutaneous melanomas arising in intermittently sun-exposed skin sites rather than 
on chronic sun-damaged skin. In particular, the missense mutation on exon 15 with a T>A 
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transversion at nucleotide 1799 is a hotspot mutation that results in the amino acid substitution from 
a valine to a glutamic acid at codon 600 (V600E), accounting for 74-92% of the BRAF mutations in 
melanoma54,58. Other less frequent somatic hotspot BRAF mutations include BRAF V600K, BRAF 
V600R, BRAF K60152. Whilst hotspot BRAF mutations and hotspot NRAS mutations are mutually 
exclusive, non-hotspot BRAF mutations co-occurred with RAS (NRAS/HRAS/KRAS) hotspot and 
NF1 mutations52. Individuals with BRAF mutant cutaneous melanomas are younger than individuals 
with RAS, NF1 or triple-WT cutaneous melanomas52.  
The BRAF V600E mutation has also been found in 73-82% of melanocytic naevi59,60 that include 
small to medium CMN24, congenital-pattern naevi26, Clark/dysplastic naevi29 and several 
dermoscopic subtypes of acquired naevi30,31 as previously described.  
NRAS (melanoma and naevi) 
The NRAS oncogene on chromosome 1p13.2 consists of seven exons and encodes a GTP-binding 
protein (neuroblastoma RAS viral oncogene homolog) involved in signal transduction within the 
MAPK pathway. Overall, 28% of primary and metastatic melanoma samples had a somatic NRAS 
mutation52. Mutations in NRAS (mainly the Q61 codon, and less frequently the G12 or G13 codon) 
have been detected in 10-27% of cutaneous melanoma52,55 and are even less frequently observed in 
acral and mucosal melanomas53. The NRAS mutation has also been linked to CMN, with a higher 
prevalence in large and giant CMN as compared to small and medium CMN (94.7 vs. 70%, 
respectively) as described above24. 
HRAS (melanoma and naevi) 
The HRAS oncogene on chromosome 11p15.5 consists of six exons and encodes a GTP-binding 
protein (Harvey rat sarcoma viral oncogene homolog) involved in signal transduction within the 
MAPK pathway. Four hotspot HRAS mutations (G13D, G13S, Q61K) were found amongst 318 
primary and metastatic cutaneous melanoma samples, and all were mutually exclusive with NRAS, 
BRAF V600 and BRAF K601 mutations52. The HRAS mutation has also been linked to Spitz 
‘starburst pattern’ naevi47 described above. 
KRAS (melanoma) 
The KRAS oncogene on chromosome 12p12.1 consists of six exons and encodes a GTP-binding 
protein (Kirsten rat sarcome 2 viral oncogene homolog) involved in signal transduction within the 
MAPK pathway. Three hotspot KRAS mutations (G12D, G12R, Q61R) were detected amongst 318 
primary and metastatic cutaneous melanoma samples, and all were mutually exclusive with NRAS, 
BRAF V600 and BRAF K601 mutations52. 
NF1 (melanoma) 
The NF1 gene on chromosome 17q11.2 is a tumour suppressor gene consisting of 60 exons and 
encodes a GTPase activating protein (neurofibromin 1) within the MAPK pathway that 
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downregulates RAS activity. Somatic mutations in NF1 have been observed in 14% of primary and 
metastatic cutaneous melanoma samples, and more than 50% of its mutations were predicted to be 
loss-of-function events52. Therefore NF1 mutations serve as an alternative way to activate the 
MAPK signalling pathway. Somatic mutations in NF1 have been found to be mutually exclusive 
with hotpot BRAF mutations; but may exist concurrently with non-hotspot BRAF/NRAS cutaneous 
melanomas, particularly in samples with a UV signature52. Loss-of-function can also be due to 
deletion. Most acral and mucosal melanomas lacked NF1 mutations53. 
KIT (melanoma) 
The KIT proto-oncogene on chromosome 4q12 consists of 21 exons and encodes a cell surface 
receptor with tyrosine kinase activity (v-kit Hardy Zuckerman 4 feline sarcoma viral oncogene 
homolog). KIT signalling leads to cell proliferation, survival, migration and differentiation. Somatic 
mutations in melanoma include exon 11 (KITL576P) and exon 13 (KITK642E), and infrequently in 
exon 17 (KIT codon 816). A higher frequency of KIT mutations have been observed in acral and 
mucosal melanomas than in cutaneous melanomas53 and loss of KIT expression is associated with 
progression of melanoma61.  
CTNNB1 (melanoma) 
The CTNNB1 proto-oncogene on chromosome 3p22.1 consists of 16 exons and encodes a cell 
adhesion molecule (Catenin beta-1) involved in the E-cadherin-mediated cell-cell adhesion system 
as well as a signal transducer in the Wnt pathway that promotes proliferation and differentiation. 
Somatic CTNNB1 mutations are infrequently found in the triple-WT subtype of cutaneous 
melanoma52. 
GNAQ (uveal melanoma and blue naevi) 
The GNAQ oncogene on chromosome 9q21.2 consists of seven exons and encodes a GTP binding 
protein (guanine nucleotide binding protein, q polypeptide) that mediates signal between the G-
protein coupled receptor (GPCR) and downstream effectors within the GPCR pathway. Somatic 
mutation in GNAQ affects codons 183 and 209 resulting in R183Q, Q209L, Q209P, Q209R, 
Q209Y. Hotspot mutations in Q209L and R183Q are associated with uveal melanoma62,63, although 
both the hotspot mutation of GNAQ209 in exon 5 and R183Q mutation in exon 4 have also been 
associated with 83% of blue ‘homogeneous blue pattern’ naevi47. Mutation in GNAQ is rarely found 
in the triple-WT subtype of cutaneous melanoma52. 
GNA11 (uveal melanoma and blue naevi) 
The GNA11 oncogene on chromosome 19p13.3 is a GNAQ homologue that consists of seven exons 
and encodes a G protein alpha unit (guanine nucleotide binding protein, alpha 11) within the GPCR 
pathway. Mutation in GNA11 is rarely found in the triple-WT subtype of cutaneous melanoma. It is 
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more frequently found in metastatic uveal melanomas rather than primary uveal melanomas64,65. It 
is also found in a minority of blue ‘homogeneous blue pattern’ naevi65. 
CDK4 (melanoma) 
The CDK4 proto-oncogene on chromosome 12q14.1 consists of 8 exons and encodes a member of 
the serine/threonine kinase family (cyclin-dependent kinase 4) involved in regulating progression 
through the G1 phase of the cell cycle (cell cycle pathway). Although a familial melanoma 
susceptibility gene with high penetrance, somatic mutations of CDK4 have been rarely found in 
sporadic cutaneous melanomas which are BRAF and NRAS wild-type52.  
TP53 (melanoma) 
The TP53 tumour suppressor gene on chromosome 17p13.1 consists of 11 exons and encodes a 
transcription factor (tumour protein 53) involved in mediating p53-dependant apoptosis (apoptosis 
pathway). Though somatic mutations of this tumour suppressor gene have been detected, it is rare in 
melanoma. Alteration of CDKN2A in 30% of melanoma may also contribute to TP53 deficiency52. 
TP53 mutations are more frequent in BRAF, RAS and NF1 cutaneous melanomas52. Individuals with 
TP53 mutant cutaneous melanomas had significantly higher mutation counts and number of C>T 
transitions52. Loss-of-function of TP53 can also be due to deletion. Mutations in TP53 have not 
been detected in acral or mucosal melanomas53 and are therefore infrequently driven by the TP53 
pathway.  
PTEN (melanoma) 
The PTEN tumour suppressor gene on chromosome 10q23.31 consists of 9 exons and encodes a 
phosphatase (phosphatase and tensin homolog) that negatively regulates intracellular levels of 
phosphatidylinositol-3,4,5-trisphosphate in cells, thus antagonising the phosphoinositol-3-kinase 
(PI3K)/AKT signalling pathway and suppresses cell survival as well as cell proliferation. A 
mutation hotspot is found in exon 5. Somatic mutations in PTEN frequently contribute to 
melanomagenesis in the context of other genetic alterations66. Loss of PTEN function can also be 
due to deletion or epigenetic changes66. Mutations in PTEN have not been detected in acral or 
mucosal melanomas53, thus these melanoma are infrequently driven by the PTEN pathway.  
CDKN2A (melanoma) 
The CDKN2A tumour suppressor gene on chromosome 9p21.3 consists of 3 exons and encodes the 
cyclin-dependant kinase inhibitor p16 (p16INK4a) and nucleolar protein p14ARF that regulate the 
cell cycle. Although a familial melanoma susceptibility gene with high penetrance, sporadic 
somatic mutations in CDKN2A are infrequently detected in cutaneous melanoma52 but are mainly 
attributed to loss of function due to homozygous deletion. Loss-of-function mutations in CDKN2A 
have been detected in triple-WT cutaneous, acral and mucosal melanomas53. 
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ARID2 (melanoma) 
The ARID2 tumour suppressor gene on chromosome 12q12 consists of 24 exons and encodes a 
DNA binding protein (AT-rich interaction domain 2) that facilitates ligand-dependant 
transcriptional activation by nuclear receptors. Loss of ARID2 function can be due to mutation and 
deletion. Mutations in ARID2 have been detected in triple-WT cutaneous, acral and mucosal 
melanomas53. 
TERT promoter (melanoma and intermediate melanocytic proliferations) 
The TERT gene on chromosome 5p15.33 consists of 16 exons and encodes the reverse transcriptase 
component and core catalytic subunit of telomerase, an RNA-dependant DNA polymerase that 
maintains telomere ends by synthesising telomeric DNA and preventing telomere erosion associated 
with cell divisions. Telomerase plays a role in cellular senescence and extends cellular life span by 
lengthening telomeres. Somatic hotspot mutations in the regulatory region of TERT (TERT 
promoter) causes enhanced expression of telomerase. TERT promoter mutations were observed in 
75% of BRAF, 71.9% of RAS, 83.3% of NF1 mutant cutaneous melanomas52; but detected in only 
6.7% of triple-WT cutaneous melanomas52. Overall, TERT promoter mutations were prevalent in 
86% of cutaneous melanomas and 11% of acral and mucosal melanomas, owing to its statistically 
significant association with melanomas with lower structural rearrangements and higher SNV 
burden53. TERT promoter mutations have also been detected in intermediate cutaneous melanocytic 
proliferations and cutaneous melanoma in situ and represent the earliest secondary alterations in 
melanoma development and progression61. 
1.5.4 Mutational signatures in melanoma 
The Catologue of Somatic Mutations in Cancer (COSMIC) mutational signatures are based on 
analysis of 10952 exomes and 1048 whole genomes across 40 distinct types of human cancer. 
These signatures reflect the different mutational processes that generate unique combinations of 
mutation types including the intrinsic slight infidelity of the DNA replication machinery, exogenous 
or endogenous mutagen exposures, enzymatic modification of DNA and defective DNA repair67. 
The profile of each signature is generated using the six classes of base substitution (C>A, C>G, 
C>T, T>A, T>C, T>G) with each substitution incorporating the bases immediately 5’ and 3’ to each 
mutated base and displayed based on the observed trinucleotide frequency68. There are a total of 30 
mutational signatures (signature 1 to 30). Signature 7, a signature associated with UVR that is 
characterised by predominance of C>T transitions and large numbers of CC>TT dinucleotide 
mutations at dipyrimidines67, is a feature in 90.7% of BRAF mutant cutaneous melanomas, 93.5% 
of RAS mutant cutaneous melanomas and 92.9% of NF1 mutant cutaneous melanomas52. In 
contrast, only 30% of triple-WT cutaneous melanomas display a UV signature52. A subsequent 
study confirmed that signature 7 was the dominant mutational signature in 97% (n=136/140) of 
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cutaneous melanomas53, contrary to 93% (n=40/43) of acral and mucosal melanomas that were 
predominated by mutational signatures other than signature 7; namely signature 1, a result of 
endogenous spontaneous deamination of 5-methylcytosine, and signature 5 which has an unknown 
aetiology and also found in other cancer types53. 
1.5.5 Copy number aberrations and structural rearrangements in melanoma 
Cutaneous melanomas have an increased amount of copy number aberrations (CNAs) and structural 
rearrangements, particularly in UV-signature deficient triple-WT cutaneous melanomas52. 
Specifically, melanomas often have focal deletions in tumour suppressor genes (e.g. CDK2NA, 
TP53, PTEN, NF1, PPP6C, ARID2)52, focal amplifications in oncogenes (e.g. MITF, BRAF, NRAS, 
HRAS, KRAS, IDH1, CDK4, TERT, MDM2, CCND1, YAP1)52, along with extensive regions of 
copy number loss-of-heterozygosity often encompassing whole chromosomal arms69. In particular, 
CNAs and complex genomic rearrangements are a hallmark of non-UVR induced acral and mucosal 
melanomas as these were more frequent in acral and mucosal melanomas than in cutaneous 
melanomas53.  
1.5.6 Current genetics in melanocytic naevi  
The focus on the genetics of melanocytic naevi thus far has been on identifying somatically 
acquired mutations found in cutaneous melanoma. Since the MAPK pathway has the vast majority 
of point mutations in melanoma, targeted sequencing of genes such as BRAF and RAS 
(NRAS/HRAS/KRAS) are the most commonly assessed genes in naevi. Attempts to molecularly 
characterise naevi have also involved mutational analyses of TP53, MC1R and targeting the high 
penetrance familial melanoma susceptibility genes CDKN2A and CDK470,71. GNAQ and GNA11 
have been assessed in blue ‘homogeneous blue pattern’ naevi due to the reminiscence of blue naevi 
with the microscopical features of the skin belonging to mutant mice harbouring germline mutations 
that increase the activity of closely related GTPases that cause dermal melanosis72. The prevalence 
of these somatic mutations in naevi have been discussed in earlier sections. 
At the time of this thesis proposal, studies in naevi have been limited to studying one or a few 
candidate genes. Subsequently, a study that sequenced 293 cancer-relevant genes (as opposed to 
whole exome/genome sequencing) in 150 areas of 27 primary melanomas and their adjacent 
precursor benign or intermediate melanocytic proliferation61 found that unequivocally benign 
melanocytic proliferations i.e. benign naevi harboured BRAF V600E with the absence of additional 
driver mutations, whereas intermediate melanocytic proliferations (not synonymous with dysplastic 
naevi) that harboured NRAS or other BRAF mutations also had additional somatic alterations; 
implicating BRAF V600E as sufficient to form a naevus and intermediate melanocytic proliferations 
as biologically distinct61. More recently, exome sequencing data of 19 naevi comprised of 11 
dysplastic naevi derived from patients with atypical naevus syndrome, 2 congenital naevi and 6 
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acquired naevi; demonstrated a substantially lower mutational load than cutaneous melanoma, and a 
different and lower frequency of UV-associated mutational signature, together with an absence of 
known melanoma driver mutations73.  
Despite these recent insights into the genomic differences between naevi and melanoma, a 
knowledge gap still exists in the understanding of the molecular hallmarks of naevi in relation to 
melanoma and the mechanisms of naevogenesis. This project seeks to address this through the 
comprehensive assessment of distinct dermoscopic naevi subsets using current sequencing 
methodologies such as whole exome sequencing (WES) and droplet digitalTM PCR (ddPCR).  
1.6 STUDY RATIONALE 
Both naevi and melanoma share overlapping driver mutations59. Most notably, the BRAF V600E 
mutation is involved in initiating melanocyte proliferation through constitutive activation of the 
MAPK pathway, but its cardinal role in the malignant transformation of naevi is questionable, as 
sustained expression induces senescence74. Furthermore, there is a high concordance rate of both 
BRAF and NRAS mutations in melanoma existing in histopathologic contiguity with naevi44. As 
most of the genomic work on naevi have been limited to known genes associated with melanoma 
such as BRAF and NRAS, this study will be a platform to identify other somatic mutations or rare 
variants in naevi that play a role in naevogenesis and its potential role in melanomagenesis, as well 
as facilitate identification of genes related to naevi growth and involution.  
Naevi consist of a morphologically heterogeneous group of benign melanocytic proliferations. 
Since the coming of age of dermoscopy, globular and reticular naevi have been postulated to pose 
different risks towards melanoma development through individual pathways of naevogenesis40, 
whereas naevi with a peripheral rim of globules have been shown to signify the growth phase of 
naevi22,45,46. Further to this, mutation in BRAF V600E has been demonstrated to influence the 
microanatomical growth pattern in different dermoscopic naevus subtypes, with BRAF V600E 
mutation more prevalent in globular naevi and naevi with a peripheral rim of globules than reticular 
naevi30,31. This study seeks to validate these BRAF V600E-associated findings, as well as explore if 
other genes other than BRAF V600E determine naevus dermoscopic pattern and histomorphology. 
This approach will reiterate the role of dermoscopy in providing further insight into naevogenesis, 
and facilitate the translation of the genetic underpinnings of naevi morphology into clinical practice, 
to aid in bedside melanoma risk assessment in the future.  
As yet, the molecular and genetic landscape of naevi is still in its infancy, and research in this 
domain using dermoscopy would be one that is relevant to undertake for the reasons presented 
above. On that account, this study has the potential to contribute to the knowledge on naevi as well 
as melanoma, serving also as a stepping-stone in the attempt towards an integrated classification 
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system for naevi that is able to encapsulate molecular findings with current knowledge of 
epidemiology, evolution, morphology and risk for cutaneous melanoma.  
1.7 AIMS AND HYPOTHESES 
1.7.1 Hypothesis development 
It has been suggested that globular and reticular naevi develop from separate developmental 
pathways of naevogenesis40 posing different risks towards melanomagenesis. Naevi with a 
peripheral rim of globules represent the growth phase of naevi with the implication that growth does 
not always indicate malignant degeneration. Few studies with small sample sizes have demonstrated 
differences in the BRAF V600E status of globular and reticular naevi31, and reported BRAF V600E 
mutation to be frequent in mixed pattern naevi with a peripheral rim of globules30. The assessment 
of these dermoscopic naevus subtypes and potential for melanomagenesis has been limited to 
studying the BRAF V600E mutation, although the role of BRAF V600E in malignant transformation 
remains inconclusive.  
The hypothesis to be tested is that globular naevi and naevi with a peripheral rim of globules will 
harbour the BRAF V600E mutation as compared to reticular naevi. Moreover, somatic mutations 
other than the BRAF V600E mutation will be present in these naevi, and some may be diagnostic 
for naevus subtype. These additional mutations may help explain the clinico-pathologic features and 
behavioural pattern demonstrated by these dermoscopic naevus subtypes. 
Given that it is possible to generate a pure population of cells from skin tissue75,76, the genotype of a 
pure clonal population of naevocytes will be able to further validate the genotypic data generated 
from naevus tissue. The hypothesis that a pure population of cells will yield a higher rate of 
detection of somatic mutations will be tested as part of this study. 
1.7.2 Aims 
Aim 1: Ascertain if there are common somatic mutations or pathway activation driving 
naevogenesis in different dermoscopic naevus subtypes.  
1. Identify somatically acquired mutations or rare variants that may be subtype specific in 
globular, reticular, and naevi with a peripheral rim of globules via WES. 
2. Validate the genetic profile of naevus tissue by comparing this to the genomic DNA from 
saliva and adjacent non-lesional skin. 
3. Validate the somatically acquired mutations or rare variants identified via WES by 
performing resequencing of targeted genes using an alternate platform in an extended set of 
naevi. 
4. Perform bioinformatic analysis of any somatic mutations identified in naevus tissue or 
cultured cells. 
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Aim 2: Contribute to previous literature correlating BRAF V600E mutation with 
dermoscopic pattern and histopathologic features.  
1. Evaluate the BRAF V600E mutation status and histopathologic features in globular, 
reticular, and naevi with a peripheral rim of globules.  
Aim 3: Compare and contrast the genotype of different dermoscopic naevus subtypes with 
histopathologic features through characterisation of cultured naevocytes. 
1. Compare the genotype and histopathologic features of globular, reticular, and naevi with a 
peripheral rim of globules.  
2. Correlate the genotype of naevus tissue with cultured naevocytes from globular, reticular, 
and naevi with a peripheral rim of globules.  
3. Correlate the genotype of cultured naevocytes with adjacent non-lesional skin cultured 
melanocytes as control.  
1.8 ACCOUNT OF RESEARCH PROGRESS 
Using ddPCR, all globular, reticular and PG dermoscopic subtypes of acquired naevi (n=40) had 
mutually exclusive BRAF or NRAS mutations, with these mutations being present in 85% and 15% 
of naevi respectively. Taken together this constitutes 100% MAPK pathway activation and is in 
keeping with the hypothesis that BRAF is acquired early in naevogenesis and support the role of the 
MAPK pathway in the development of naevi. Specifically, the BRAF mutations comprised BRAF 
V600E (c. 1799T>A) in 70% of naevi, BRAF V600E (c.1799_1800delTGinsA) in 7.5% of naevi 
and BRAF V600K mutations in 7.5% of naevi. The data also revealed that a predominantly dermal 
growth pattern or the presence of large junctional nests to be significantly associated with a BRAF 
mutation. No other significant correlation was found between BRAF mutations and histopathologic 
characteristics in the study samples. 
Upon WES, globular, reticular and PG dermoscopic subtypes of acquired naevi (n=30) had 30-668 
somatic mutations (median, 256) or 0-9 mutations per megabase (median, 3).  C>T transitions were 
confirmed to be the most prevalent single-nucleotide variant class and overall the analysed naevi 
share many similarities to the mutation frequency distribution in cutaneous melanoma. Ultraviolet 
radiation (UVR)-related mutation signature was the dominant mutation signature in 97% of naevi, 
although there was a 93% and 30% prevalence of age-related and defective DNA repair-related 
signature respectively in the assessed naevi. C>T transition was also the dominant base substitution 
in adjacent non-lesional skin (n=30), although this only culminated in a UVR-related mutation 
signature in 10% of adjacent non-lesional skin. Remarkably, defective DNA repair signatures were 
more frequently observed in adjacent non-lesional skin than in the assessed naevi, in addition to 
100% age-related mutation signature prevalence. This suggests that in most cases, acquired naevi 
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occur following cumulative exposure to UVR together with defective DNA repair mechanisms in 
normal skin melanocytes. Mutually exclusive mutations in BRAF and NRAS were the most frequent 
driver mutations in the analysed naevi. Other driver genes were also detected at a lower prevalence; 
including well-known genes (e.g. MET and GRIN2A) and novel genes (e.g. HDAC9, MYH11, and 
DCC). There was absence of the non-coding mutation in TERT promoter in the naevi (n=30). 
Globular naevi that are characterised by a dermal growth pattern, largely absent architectural 
disorder or cytological atypia and high naevus cell density in this dataset was 92% BRAF V600E/K 
mutant and are associated with a higher somatic mutation burden. In particular globular naevi have 
a significantly higher proportion of T[C>T]A transitions that culminated in a greater proportion of 
UVR-related mutation signature, but are largely genomically silent containing only minor CNAs. 
Reticular naevi were 67% BRAF V600E/K mutant and 33% NRAS mutant, whereas PG naevi were 
100% BRAF V600E mutant and had a significantly higher proportion of C>G and T>A 
transversions. Reticular and PG naevi with an epidermal growth pattern typically characterised by 
junctional nests in this dataset shared a significantly higher proportion of indels and large regional 
genome-wide CNAs, involving combined loss of melanoma-related tumour suppressor genes and 
oncogenes. This reveals that CNA events that are absent or balanced in clonally expanded 
melanocytes lead to naevogenesis. Moreover, differences in the mutation frequency in the various 
dermoscopic naevi subtypes suggest that specific mutation types may contribute to the development 
of distinct dermoscopic and histopathologic naevus phenotypes. 
The successfully cultured naevi (n=6/17) were BRAF V600E (c.1799T>A) or BRAF V600K mutant 
reticular and PG naevi with nest formation of junctional melanocytes on histopathology. Globular 
naevi that had a predominantly dermal growth pattern that corresponded to a higher percentage 
naevus cell density (naevus cellularity) on histopathology, and had a higher BRAF V600E fractional 
abundance based on ddPCR data; did not propagate in culture (n=8/8). Based on WES, there was an 
approximately 3 to 4 fold higher BRAF V600E (c.1799T>A) mutant frequency in the cultured 
naevocytes as compared to naevus tissue in 2/5 paired naevi. The BRAF V600E mutation was 
present in naevus tissue but absent in cultured naevocytes in 2/5 naevi, whereas 1/5 naevi had the 
same BRAF V600K mutant frequency in naevus tissue and cultured naevocytes. Notably, the 
majority of somatic mutations detected in the cultured naevocytes were absent in naevus tissue in 
all of the successfully cultured and sequenced naevi. Given that a different portion of the naevus 
was subjected to culture as compared to the naevus tissue that was sequenced, the intratumoral 
heterogeneity provides evidence for the presence of polyclonal cell populations in naevi. 
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CHAPTER 2  
Materials and methods  
2.1 STUDY DEVELOPMENT  
I carried out the literature search that forms the basis of the work contained in this thesis. My 
advisory team (Professor H. Peter Soyer, Associate Professor Rick A. Sturm and Dr Mitchell S. 
Stark) provided input into the concept and design of this work. 
2.2 CLINICAL WORK-UP 
Patient recruitment into clinical studies and surgical excisions required specialist skills. Under the 
guidance of my principal advisor Professor H. Peter Soyer, I recruited all the participants in this 
study, performed patient interviews, clinical data collection, photodocumentation, shave excisional 
biopsies, specimen dissection and arranged histopathological diagnosis. 
2.2.1 Naevi collection 
This study includes 40 freshly collected acquired naevi specimens with the globular (n=13), 
reticular (n=15) and peripheral rim of globules (PG) (n=12) dermoscopic patterns identified from a 
database of prospectively imaged naevi from patients NHMRC funded project “pigmentation 
genotypes and phenotypic correlations with dermoscopic naevus types and distribution”1,2 at 
Dermatology Research Centre (The University of Queensland, School of Medicine). Informed 
consent was obtained from all study participants and the study was carried out in accordance with 
the Declaration of Helsinki.  
2.2.2 Clinical data collection and photodocumentation 
The dermoscopic pattern of each naevus was assessed clinically using the DermLite DL3 
dermoscope (3Gen, USA). Participant age, gender, anatomical location and measurement of each 
naevus were documented. Clinical photos were taken of the anatomical location and close-up 
features of each naevus using the Panasonic Lumix DMC-LX5 (Panasonic Corporation, Japan) 
digital camera. The DermLite cam® camera (3Gen, USA) was used to obtain clinical macro photos 
at a standardised distance, and dermoscopic images taken at 10X magnification under cross-
polarised light. Digital dermoscopic images of a subset of naevi were captured using the 
FotoFinder® dermoscope (FotoFinder Systems, GmbH).  
2.2.3 Tissue sampling (Figure 6) 
Shave excision of each naevus was performed with either a 2mm or 3mm margin using sterile 
technique under local anaesthetic. Each tissue sample was bisected. One portion of the tissue was 
chemically fixed in formalin and sent to an external pathology laboratory (IQ Pathology, Brisbane, 
Australia) for conventional histopathology and routine reporting by a board-certified 
dermatopathologist. The other half of the tissue was retained for genomic work-up and dissected to 
 48 
isolate the naevus from adjacent non-lesional skin (n=40). In a subset of naevi, the portion retained 
for genomic work was further bisected and a quarter subjected to cell culture (n=17).  
 
 
2.2.4 Tissue preparation 
The tissue was either flash frozen at -80°C (n=20) or preserved in RNAlater® (Thermo Fisher 
Scientific Inc, USA) prior to storage at -80°C (n=20). Some of the tissue samples initially frozen at 
-80°c were subsequently treated with RNAlater®-ICE (Thermo Fisher Scientific Inc, USA) prior to 
DNA extraction to facilitate co-extraction of DNA with RNA and miRNA for future studies beyond 
the scope of this MPhil project (n=10).  
2.2.5 Assessment of histopathologic sections  
The haematoxylin-eosin (H&E)-stained histopathologic sections of naevi were scanned using either 
the Aperio® (Leica Biosystems, Nussloch, Germany) or Olympus VS120® (Olympus Corporation, 
Tokyo, Japan) commercially available virtual microscopy slide scanner with assistance from Dr 
Figure 6. Sectioning of naevus tissue for histopathologic assessment, genomic work and cell 
culture.  
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Miko Yamada. My principal advisor Professor H. Peter Soyer assessed the histopathologic 
characteristics according to a method adapted from Marchetti et al3 (Table 1) and estimated the 
naevus cellularity (percentage naevus cell density) histopathologically. 
Table 2. Histopathologic assessment method adapted from Marchetti et al.3 
Microanatomical growth pattern 1 Predominantly or entirely epidermal 
2 Equivalent epidermal and dermal components 
3 Predominantly or entirely dermal 
Nest formation of junction 
melanocytes 
0 Absence of junctional melanocytes 
1 Lentiginous growth pattern with absence of nests 
2 Combination of lentiginous growth and small nests 
3 Predominantly large junctional nests 
Architectural disorder and 
cytological atypia 
0 Absent 
1 Present 
 
2.3 GENOMIC WORK-UP 
2.3.1 DNA extraction 
Tissue 
I performed DNA isolation on 60% of tissue samples. Ms Kasturee Jagirdar performed DNA 
isolation of 25% of tissue samples. Dr Lisa N. Tom performed DNA isolation of 15% of tissue 
samples. DNA extraction was performed either using the QIAamp DNA Mini Kit (QIAGEN, 
Hilden, Germany) (n=11) or the AllPrep DNA/RNA/miRNA Universal Kit (QIAGEN, Hilden, 
Germany) according to manufacturer’s protocol (n=29), amended according to sample size. Briefly, 
the tissue specimens were placed in Buffer RLT Plus (QIAGEN, Hilden, Germany) and β-
mercaptoethanol and then disrupted and homogenised using a bullet blender (Next Advance, NY, 
USA). The debris was pelleted and the supernatant was collected for co-extraction. RNA and 
miRNA will be stored for future research beyond the scope of this MPhil project. 
Saliva 
As the participants were part of the NHMRC-funded project “Pigmentation genotypes and 
phenotypic correlations with dermoscopic naevus types and distribution”1,2, saliva DNA samples 
were already available. These were prepared using the Oragene-DNA self-collection kit (DNA 
Genotec, Ottawa, ON, Canada) and Ms Kasturee Jagirdar extracted the DNA by following the 
manufacturer’s instructions. 
Cultured cells 
Ms Kasturee Jagirdar performed DNA extraction on cultured naevocytes and adjacent non-lesional 
skin cells using the QIAGEN QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) according to 
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manufacturer’s protocol. A pellet of the cultured cells was obtained by scraping the cells in PBS 
and spinning at 13,000 rpm for 5 minutes.  
2.3.2 DNA quantification 
DNA was quantified using either a spectrophotometer (NanoDrop™ Lite, Thermo Scientific, 
Waltham, MA, USA) or quantitative fluorometer (Qubit® 2.0, Life Technologies, Carlsbad, CA, 
USA).  
2.3.3 Droplet Digital™  PCR  
My advisor Dr Mitchell S. Stark provided input into the design and selection of droplet digital™ 
PCR (ddPCR) probes. Dr Lisa N. Tom and my advisor Dr Mitchell Stark performed ddPCR and 
analysed the ddPCR reaction. Mutation detection was performed on the extracted DNA samples 
using the QX200 ddPCR system. Briefly, ddPCR probes (BioRad, California, USA) specific to the 
common BRAF [V600E (c. 1799T>A) and V600K] were used to confirm the BRAF mutation. Next, 
all BRAF wild-type samples were assessed using a screening kit or mutation-specific probes for 
NRAS codons 12/13 and 61.  
Specifically, PrimePCR mutation assays BRAF p.V600E c.1799T>A (dHsaMDV2010027), BRAF 
p.V600K (dHsaMDV2010035), NRAS p.G13C (dHsaMDV2516776), NRAS p.Q61K c.181C>A 
(dHsaMDV2010067), NRAS p.Q61R c.182A>G (dHsaMDV2010071), NRAS p.Q61L c.182A>T 
(dHsaMDV2010069) and the NRAS G12/G13 screening kit #12001627 (Bio-Rad), which detects 
G12A, G12C, G12D, G12S, G12V, G13D, G13R, and G13V mutations were used according to the 
manufacturer’s protocol. ddPCR Supermix for Probes (no dUTP) was used to prepare reaction 
mastermixes with 50ng of DNA template used in each reaction. Template DNA was digested within 
the ddPCR reaction using the restriction enzyme recommended for each assay at a concentration of 
2U/reaction. Rare event detection (RED) settings were selected for data collection using Quantasoft 
version 1.7.4 software (Bio-Rad). Fractional abundance (FA) of mutations was determined by 
Quantasoft software using the formula FA = (a/a+b), where a = number of mutant DNA molecules 
and b = wild-type DNA molecules.  
To allow for confident calling of mutation status, confirmed BRAF and NRAS mutant and wild-type 
samples were used to set thresholds for identification of mutation-positive droplets. In addition, 
multiple wild-type control wells were used to identify the false positive rate for each individual 
probe. All of the reported mutations that were present showed positive droplets at higher 
fluorescence intensity and frequency as compared to wild-type controls. 
2.3.4 Sanger Sequencing 
BRAF 
Ms Kasturee Jagirdar performed polymerase chain reaction of BRAF exon 15 by using the forward 
primer sequence 5’- TCATAATGCTTGCTCTGATAGGA-3’ and the reverse primer sequence 5’-
 51 
GGCCAAAAATTTAATCAGTGGA-3’. The PCR conditions were an initial denaturation of 5 
minutes at 94°C, followed by 40 cycles of denaturation at 94°C for 40 seconds, annealing at 60°C 
for 40 seconds and extension at 72°C for 1 minute and a final step of 7 minutes at 72°C. The PCR 
products were run on a 2% agarose gel and were purified using the QIAquick Gel Extraction Kit 
(QIAGEN, Australia). 10ng of the purified DNA was used for a sequencing reaction with Big Dye 
Terminator v3.1 and sent to the Australian Equine Genomics Research Centre (University of 
Queensland, Australia). The sequencing data was analysed using Sequencher 5.4 software with the 
BRAF reference sequence (chr7:140,452,836-140,453,436, hg19) from the NCBI gene database.  
TERT promoter 
Ms Kasturee Jagirdar amplified the TERT promoter region using forward (5’- 
ACGAACGTGGCCAGCGGCAG-3’) and reverse (5’- CTCCCAGTGGATTCGCGGGC-3’) 
primer sequences designed using Primer3web (v4.0.0) software. To increase the specificity of the 
primers, a touchdown PCR protocol was employed with a cycling routine of two cycles at each 
annealing temperature commencing at 69°C, decreasing by 1°C steps (69°C-63°C), followed by 20 
cycles at the optimal temperature (62°C). All other cycling conditions were as per manufacturers 
protocol (Thermo Fisher Scientific). PCR reactions consisted of 25-50ng of DNA, 0.5µM of each 
primer, 200µM dNTPs (Thermo Fisher Scientific), together with 0.4U of Phusion Hot start II High-
Fidelity DNA polymerase (#F-549, Thermo Fisher Scientific), 5X Phusion GC buffer 
(supplemented with MgCl2; #F-519) and 5% DMSO. The 369bp PCR products were 
electrophoresed on a 2% TAE agarose gel, purified using the QIAquick Gel Extraction Kit 
(QIAGEN), then sequenced using the BigDye™ Terminator v3.1 Cycle Sequencing Kit (Thermo 
Fisher Scientific) as per manufacturer’s instructions. Agencourt CleanSEQ (Beckman Coulter Life 
Sciences) purified products were run on the 3730-series Genetic Analyzer (Thermo Fisher 
Scientific) by the Australian Equine Genetics Research Centre (AEGRC, Brisbane, Australia). All 
TERT-promoter sequence chromatograms were analysed using Sequencher 5.4 software (Gene 
Codes Corporation) in comparison with hg19 reference sequence (chr5: 1,295,022-1,295,495).  
2.3.5 Whole exome sequencing and next-generation sequencing data analysis 
DNA from matched saliva (n=30), naevi (n=30), and adjacent non-lesional skin (n=30), cultured 
naevocytes (n=5) and adjacent non-lesional skin melanocytes (n=5) were sent to fee-for-service 
provider Macrogen Inc (Seoul, Rep. of Korea) for exome library preparation (SureSelect V5+UTR; 
Agilent, CA, USA) and paired-end 100bp sequencing using the HiSeq4000 system (Illumina, CA, 
USA). Saliva-derived and tissue/naevocytes/melanocytes DNA were sequenced at a depth of ≥60x 
≥100x on-target coverage respectively (or 100x or 200x raw coverage).  
My advisor Dr Mitchell S. Stark analysed all raw sequence reads (fastq) in-house by using standard 
bioinformatic software run on the Translational Research Institute (TRI, Brisbane, Australia) high 
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performance computing cluster. Briefly, the paired-end sequence reads were aligned to the human 
reference genome (hg19) using the BWA alignment software4 (https://sourceforge.net/projects/bio-
bwa/files/), then filtered, sorted, realigned and depth of coverage determined using picard tools 
(https://github.com/broadinstitute/picard), samtools5 
(https://sourceforge.net/projects/samtools/files/), and the GATK toolkit 
(https://software.broadinstitute.org/gatk/) respectively. Variants were called using samtools5 
mpileup and VarScan26 (https://github.com/dkoboldt/varscan) to generate a VCF file. All variants 
were annotated using the hg19 build of ANNOVAR7 including single-nucleotide (SNP) and 
insertion/deletion (in/del) polymorphism databases (dbSNP138, 1000 genomes project 
1000g2014oct_eur build, and Exome  Aggregation   Consortium   (ExAC) Non-Finnish Europeans 
(NFE). In-silico prediction of variant function was assessed using the ANNOVAR7 version of 
dbNSFP8 including the SIFT9, Polyphen210, and MutationTaster11 algorithms. 
 
Bioinformatic analysis was conducted by my advisor Dr Mitchell S. Stark. This required 
specialist skills to adhere to the timeframe of this study. Dr Stark kept me updated during the 
process and we met at regular intervals to discuss and interpret the data. 
 
2.3.6 Somatic variant calling and filtering 
The somatic variants present in the naevi and adjacent non-lesional skin samples were determined 
firstly by filtering out all variants that were present in the matching saliva-derived germline DNA 
followed by all variants that were present in 1000g2014oct_eur and ExAC NFE databases. Variants 
present in dbSNP 138 were not used as a filter due to the presence of somatic mutations (eg. BRAF 
V600E). Accordingly, a proportion of the variants presented in Tables S3 and S5 in the published 
version of Chapter 412 may indeed be polymorphisms. Next, any variant present in a pool of 30 
adjacent non-lesional skin samples were removed from each of the naevi samples which resulted in 
a list of somatic variants present only in the naevus tissue and not from adjacent non-lesional skin 
contamination. Next, all somatic variants present in the naevi and adjacent non-lesional skin were 
filtered further to include only those with a total of ≥10 reads, an alternative read frequency of ~3% 
(based upon known a mutation in NRAS Q61K previously determined by ddPCR13), a variant 
p≤0.05, and an alternate Phred base quality of 30.  
2.3.7 Detection of known mutations 
In order to test the sensitivity of the exome sequencing depth for identifying somatic mutations in 
BRAF or NRAS present in the naevi13, the Integrative Genome Viewer (IGV, Broad Institute) was 
first used to visualise the BAM files at specific codons. BRAF V600E/K mutations were detectable 
in all samples (26/26; Table S2 in the published version of Chapter 412) and NRAS G13C and 
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Q61L/K/R were detectable in the remaining 4/4 samples (Table S2 in the published version of 
Chapter 412). The droplet digital™ PCR (ddPCR) methodology employed in Chapter 313 detected 
additional NRAS G13C mutations in samples with codon 61 mutations which were not detectable in 
the exome dataset as these mutations were less than the limit of detection (~1% mutant frequency). 
Furthermore, the NRAS Q61L mutation detected in 903JA naevus 33 via exome sequencing was not 
validated using ddPCR; instead this naevus was found to have an NRAS G13C mutation. Therefore 
the NRAS Q61L mutation found on exome sequencing is possibly a false positive result. Next, the 
presence of the mutations was validated in the stringently filtered dataset as described. BRAF/NRAS 
mutations were detectable in 17/30 naevi with 13/30 naevi not passing filtering due to low mutant 
allele frequency (n=10/13) and were filtered out during variant calling; or the mutant call had a 
p>0.05 (n=3/13) as determined via VarScan26. 
2.3.8 Mutation signature analysis 
Somatic single-nucleotide variants (SNVs) in the naevi were identified from the exome pull-down 
region (5`UTR, exon, and 3`UTR). Filtered somatics SNVs present in the naevi and adjacent non-
lesional skin were imported into the deconstructSigs14 package using R 3.4.0 for Windows 
(https://github.com/raerose01/deconstructSigs) and allows for individual samples to be analysed to 
observe inter-sample variability. Mutation signatures were determined by using the framework of 
30 COSMIC signatures (http://cancer.sanger.ac.uk/cosmic/signatures) collated in the 
deconstructSigs package. Somatic mutations present in melanoma datasets used as a comparison 
were downloaded from 
ftp://ftp.sanger.ac.uk/pub/cancer/AlexandrovEtAl/somatic_mutation_data/Melanoma/ and imported 
into the deconstructSigs package as described.  
2.3.9 Copy number analysis 
Copy number aberrations were determined via the CNVkit15 package 
(https://github.com/etal/cnvkit) and run using Python 2.7. Briefly, matching naevi and adjacent non-
lesional skin BAM files, with duplicates marked and sorted (see methods above) were analysed 
within CNVkit according to standard methods. The matching adjacent non-lesional skin was used 
as the background normal. Naevus cell content was estimated based upon BRAF mutation 
frequency as determined by methods previously reported16. In the absence of BRAF mutation, 
tumour cell fraction (naevus cellularity or percentage naevus cell density) was estimated from 
H&E-stained histopathologic sections. A segmentation file (Table S6 in the published version of 
Chapter 412) was compiled from all naevi to allow for genome-wide visualisation (Figure 3 in the 
published version of Chapter 412) in the IGV. Genes involved in regions of gain (log2 ≥3) and loss 
(log2 ≤-1) summarised in Table S7 in the published version of Chapter 412, were those commonly 
mutated in melanoma17. The effect of copy number on RNA expression in exemplar genes derived 
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from Table S7 in the published version of Chapter 412 and shown in Supplementary Figures 1 and 2 
in the published version of Chapter 412 was determined using the melanoma TCGA datasets 
accessed via the cBioPortal for Cancer Genomics (http://www.cbioportal.org/)18,19.  
2.4 PRIMARY CELL CULTURE 
With input from my advisor Associate Professor Richard A. Sturm, Dr Stephen Ainger and Ms 
Hilary Yong performed the cell culture experiments on matched naevus and adjacent non-lesional 
skin (n=17) using an adapted protocol described previously20,21 based on methods described by Soo 
et al22,23 and McNeal et al24. Naevus and adjacent non-lesional skin tissue were individually stored 
in MCDB + penicillin/streptomycin media while in transit. Naevus and adjacent non-lesional skin 
tissue (2 samples) were then treated with 2 mls of 20mM EDTA solution in individual sterile petri 
dishes for 2 minutes and rinsed off with 2mls of PBS solution in a tissue culture hood. The adjacent 
non-lesional skin tissue was bisected whilst still in the PBS (yielding 2 samples of adjacent non-
lesional skin), and naevus and bisected adjacent non-lesional skin tissue (total of 3 samples per 
matched naevus and adjacent non-lesional skin) were individually incubated at 37°c for 3 hours in 
Eppendorf tubes containing 100ul of Dispase II solution (Roche)(enzymatically dissociated).  
After 3 hours of incubation, each sample was mechanically separated (vortexed for 15 seconds 
each) into fine pieces. Thereafter using a pipette tip, each sample was mechanically stirred until the 
epidermis was separated from the dermis, rendering the mixture cloudy. The Eppendorf tube 
mixture together with 2mls of melanoblast culture media was then transferred to a 12-well culture 
plate prepared with a collagen matrix (GIBCO) and incubated at 37°C for 72 hours. After a few 
days when the culture reaches about 50% confluency, the well containing naevus tissue cells were 
treated with lentivirus particles containing a CDK4 R24C vector, and the wells containing adjacent 
non-lesional skin tissue cells were treated with viruses containing CDK4 R24C and empty vectors. 
2.5 STATISTICAL ANALYSIS 
Statistical analysis was performed with GraphPad Prism version 7.0 or version 7.03 for Windows 
(La Jolla, California, USA) with input from my advisor Dr Mitchell S. Stark. A p-value <0.05 was 
considered statistically significant. Please refer to Chapters 3, 4 and 5 for specific tests used.  
2.6 TABLES AND FIGURES 
I composed all the tables and figures in this thesis with the exception of Figure 2 in the publication 
included in Chapter 3 of this thesis under Appendix B (Dr Lisa N. Tom and Ms Kasturee Jagirdar), 
Figure 11 (Dr Mitchell S. Stark), Figures 14 and 15 (Ms Kasturee Jagirdar), Figure 16 (Dr Lisa N. 
Tom), the tables and figures in the published version of Chapter 4 under Appendix C (Dr Mitchell 
S. Stark). I wrote the figure and table legends in this thesis with the exception of the legend for 
Figure 11 (Dr Mitchell S. Stark) and the figure and table legends in the published version of 
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Chapter 4 under Appendix C (Dr Mitchell S. Stark). I composed the tables using Microsoft word 
document and created the figures using either Adobe Illustrator CC 2017 or Microsoft PowerPoint. 
2.7 DATA INTERPRETATION AND THESIS WRITING 
I interpreted the data generated from this study and wrote this thesis with input from my advisory 
team (Professor H. Peter Soyer, Associate Professor Rick A. Sturm and Dr Mitchell S. Stark). A 
published version of Chapter 4 is attached in Appendix C. Chapter 4 of this thesis provides a more 
specific and in-depth analysis and discussion of key points specifically relevant to Aim 1 (ascertain 
if there are common somatic mutations or pathway activation driving naevogenesis in different 
dermoscopic naevus subtypes) of this thesis. 
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CHAPTER 3  
The BRAF and NRAS mutation prevalence in dermoscopic 
subtypes of acquired naevi reveals constitutive mitogen-
activated protein kinase pathway activation 
 
Tan JM, Tom LN, Jagirdar K, Lambie D, Schaider H, Sturm RA, Soyer HP and Stark MS. The 
BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals 
constitutive mitogen-activated protein kinase pathway activation. Br J Dermatol. 2018;178(1):191-
197. (British Journal of Dermatology Editors’ Choice January 2018) – Appendix B. 
 
3.1 RELEVANCE OF THESIS AIMS 
This chapter relates to thesis aims 1 and 2.  
Aim 1: Ascertain if there are common somatic mutations or pathway activation driving 
naevogenesis in different dermoscopic naevus subtypes.  
and 
Aim 2: Contribute to previous literature correlating BRAF V600E mutation with 
dermoscopic pattern and histopathologic features.  
At the time of the study design, the frequency of somatic BRAF mutations in dermoscopic subtypes 
of acquired naevi had been investigated using a variety of methodologies1,2, whereas NRAS 
mutation prevalence according to dermoscopic naevus pattern has not been evaluated. NRAS are 
often associated with medium and large congenital melanocytic naevi (CMN), melanoma, and naevi 
associated with a melanoma3. One study that employed Sanger sequencing and ultradeep 
pyrosequencing (UDPS) found BRAF mutations to be more frequent in globular naevi and naevi 
with a peripheral rim of globules (PG), but could not draw a conclusion for reticular naevi due to 
the inconsistency in the BRAF mutation prevalence in reticular naevi obtained by Sanger 
sequencing and UDPS1. Another study that utilised immunohistochemistry to investigate BRAF 
V600E expression between globular and reticular naevi reported that globular naevi that 
corresponded to a predominantly dermal growth pattern or the presence of large junctional nests 
were at least three times more likely to significantly express BRAF V600E than reticular naevi2.  
This chapter focuses on targeted sequencing of the common BRAF and NRAS mutations using the 
quantitative QX200 droplet digital™ PCR (ddPCR) system, a highly sensitive method capable of 
single-cell sequencing. Of note, whole exome sequencing used to assess the genomic landscape of 
the naevi (see Chapter 4) also included analysis of common driver mutations performed on a 
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smaller number of tissue samples (n=30) to address Aim 1. In the data presented in this chapter 
(Chapter 3), mutually exclusive BRAF and NRAS mutations were present in 85% and 15% of naevi 
respectively. Taken together these constitute 100% mitogen-activated protein kinase pathway 
activation. The BRAF mutation was present in 92% globular and 100% PG naevi, whereas reticular 
naevi were 67% and 33% BRAF and NRAS mutant respectively. These data contribute to Aim 1. 
Specifically, the BRAF mutations comprised BRAF V600E (c. 1799T>A) in 70% of naevi, BRAF 
V600E (c.1799_1800delTGinsA) in 7.5% of naevi and BRAF V600K mutations in 7.5% of naevi. 
The data also revealed that a predominantly dermal growth pattern or the presence of large 
junctional nests to be significantly associated with a BRAF mutation. No other significant 
correlation was found between BRAF mutations and histopathologic characteristics in the study 
samples. These data contribute and satisfy Aim 2. This BRAF and NRAS genotype together with the 
histopathological characteristics of globular, reticular and PG naevi subjected to cell culture 
experiments (n=17) was observed to affect the propagation of cells in culture, helping to address 
Aim 3 (see Chapter 5). Table 3 summarises the demographic data, dermoscopic and histopathologic 
characteristics, BRAF and NRAS status of the 40 acquired naevi as well as specifies naevi that were 
subjected to whole exome sequencing (see Chapter 4) and cell culture experiments (see Chapter 5). 
3.2 CONTRIBUTION OF CANDIDATE 
I developed the concept and study design with discussion with my supervisors. I performed all of 
the clinical work that includes identifying the naevi, photodocumentation, excising the naevi and 
dissecting the tissue. I performed DNA isolation on 60% of tissue samples. I performed the 
statistical analysis and interpreted the data. I prepared the manuscript, composed Figure 1 from 
clinical photographs I took, created all the tables, and wrote the figure and table legends.  
3.3 ACKNOWLEDGEMENT OF CONTRIBUTION OF CO-AUTHORS  
Professor H. Peter Soyer (Soyer HP), Associate Professor Rick A. Sturm (Sturm RA), Dr Mitchell 
S. Stark (Stark MS) and Associate Professor Helmut Schaider (Schaider H) provided input into the 
conception and design. Professor H. Peter Soyer (Soyer HP), Associate Professor Rick A. Sturm 
(Sturm RA), Dr Mitchell S. Stark (Stark MS) reviewed and edited draft versions of the manuscript. 
Dr Lisa N. Tom (Tom LN) and Ms Kasturee Jagirdar (Jagirdar K) helped to draft the methods and 
create Figure 2. Professor H. Peter Soyer (Soyer HP) and Dr Duncan Lambie (Lambie D) assessed 
the histopathology images. Dr Mitchell S. Stark (Stark MS) and Dr Lisa N. Tom (Tom LN) 
performed ddPCR and assisted with the analysis of ddPCR. Dr Mitchell S. Stark (Stark MS) 
assisted with the interpretation of ddPCR data. Dr Lisa N. Tom (Tom LN) assisted with DNA 
isolation of 15% of tissue samples. Ms Kasturee Jagirdar (Jagirdar K) assisted with DNA isolation 
of 25% of tissue samples and Sanger sequencing. A statement on the contribution of all co-authors 
is included within the preliminary pages of this thesis. 
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Table 3. Demographic data, dermoscopic and histopathologic characteristics, BRAF and NRAS status of the 40 sampled acquired naevi. 
Exome sequencing results and cell culture results are described in Chapters 4 and 5 respectively.  
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152 G C 3 2 0 50 42 Back M 0 21.4 . . . . . . √ × 
155 R J 1 2 1 <5 42 Back M 0 6.9 . . . . . . √ × 
28RH 135 G I 3 0 0 70 55 Back M 27.4 . . . . . . . √ × 
110 R C 1 2 1 <5 55 Back M 17.9 . . . . . . . √ × 
39RB 6 G I 3 0 0 80 60 Chest M 19.7 . . . . . . . √ • 
52JH 40 G I 3 0 0 80 60 Back F 33 . . . . . . . √ • 
61JB 115 G C 3 1 0 60 66 Back M 22.8 . . . . . . . √ • 
133 G I 3 0 0 50 66 Back M * . . . . . . * √ • 
111CM 3 G I 3 0 0 70 35 Neck M 27.1 . . . . . . . √ • 
21 G I 3 0 0 60-
70 
35 Back M 21.2 . . . . . . . √ • 
158RP 4 G I 3 0 0 60-
70 
65 Ext M 21 . . . . . . . √ • 
78 R J 1 2 1 <5 65 Back M 1.55 . . . . . . . √ √ 
510AN 2 G I 3 0 0 70 65 Ext M 30.1 . . . . . . . √ • 
23 R C 1 1 0 <5 65 Abdo M 0 3.23 . . . . . . √ √ 
736TP 3 G C 3 2 1 70 41 Abdo M 20.4 . . . . . . . √ × 
13 R J 1 2 1 10 41 Back M 6.1 . . . . . . . √ × 
1301PP 7 G I 3 0 0 30 47 Abdo M 0 0 0.05 0.03 0.21 0 0 . × × 
1346KJ 30 G I 3 0 0 50 38 Ext F 27.3 . . . . . . . √ × 
7 R C 2 2 0 10 38 Back F 5.5 . . . . . . . √ √ 
 61 
  Table 3 continued… 
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130MV 160 R C 3 2 1 40 44 Back M 13.5 . . . . . . . √ × 
155IN 30 R C 3 2 1 30 56 Ext M 4.4 . . . . . . . √ × 
673PS 1 R J 1 1 0 <5 60 Chest M 0 0 0.09 0.031 0 0 0 . √ × 
2 R J 1 2 1 <5 60 Abdo M 0 0 0.06 0.08 4.9 0 0 . √ × 
695MB 59 R C 2 2 1 10 28 Ext M 12.2 . . . . . . . √ √ 
747LH 133 R J 1 1 0 <1 66 Ext F 0 0 0.15 0.06 0 0 0 . × × 
772DW 75 R C 3 2 1 60 67 Back M 21.3 . . . . . . . √ × 
774AS 17 R C 1 2 1 <1 55 Ext M 0 0 0.14 0.06 0 0 2.42 . √ × 
903JA 33 R J 1 2 1 <1 54 Back M 0 0 0.16 0.1 0 0 0 . √ • 
822MT 10 PG C 2 2 0 30 26 Abdo F 21.6 . . . . . . . √ √ 
Rab PG J 1 3 0 10 26 Abdo F 2.6 . . . . . . . √ × 
970HH 75 PG C 1 3 0 10 39 Back F 7.8 . . . . . . . × × 
1030N
W 
28 PG C 3 2 0 10 26 Back F 12.4 . . . . . . . × √ 
54 PG J 1 3 0 5 26 Back F * . . . . . . * × • 
1048KP Rab PG C 2 2 0 30 33 Abdo F 14.7 . . . . . . . × × 
1062DM 76 PG C 1 2 1 20 33 Abdo M 6.9 . . . . . . . √ • 
1078JG 47 PG J 1 3 0 5-10 40 Back M 6.4 . . . . . . . × × 
100 PG C 2 2 0 10 40 Ext M * . . . . . . * √ × 
1294HS 20 PG J 1 2 0 <5 36 Back F 3.04 . . . . . . . × × 
1427RB Rab PG J 1 3 0 10 36 Abdo M 5 . . . . . . . × × 
Rch PG J 1 2 0 5 36 Chest M 4.3 . . . . . . . × × 
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Abbreviations: Abdo, abdomen; C, compound naevus; Ext, extremity; F, female; G, globular naevus; I, intradermal naevus; J, junctional naevus; M, 
male; PG, naevus with a peripheral rim of globules; R, reticular naevus. 
Columns from left to right:  
(1) Patient ID 
(2) Naevus ID; 
(3) Dermoscopic subtype of naevi; 
(4) Histopathological subtype of naevi; 
(5) Predominant microanatomical growth pattern on histopathology (1 = predominantly or entirely epidermal, 2 = equivalent epidermal and dermal 
components, 3 = predominantly or entirely dermal); 
(6) Nest formation of junctional melanocytes on histopathology (0 = absence of junctional melanocytes, 1 = lentiginous growth pattern with absence of 
nests, 2 = combination of lentiginous growth and small nests, 3 = predominantly large junctional nests); 
(7) Architectural disorder and cytological atypia on histopathology (0 = absent, 1 = present); 
(8) Naevus cellularity (%) 
(9) Age; 
(10) Location of naevi; 
(11) Sex; 
(12-13) BRAF ddPCR mutation assay results (fractional abundance);  
(14-18) NRAS ddPCR mutation assay results (fractional abundance); 
(19) Sanger sequencing results (* = V600E c. 1799_1800delTGinsAA);  
(20) Exome sequencing status (√ = sequenced, × = not sequenced); 
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(21) Cell culture status (√ = propagated, • = subjected to culture experiment but did not propagate, × = not subjected to culture experiment)
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CHAPTER 4  
Whole exome sequencing of dermoscopic subtypes of acquired 
naevi identifies mechanisms for naevogenesis that provide 
insight into their evolution and life cycle and maintenance of 
benign melanocytic proliferations 
4.1 RELEVANCE OF THESIS AIMS 
This chapter relates to thesis aim 1.  
Aim 1: Ascertain if there are common somatic mutations or pathway activation driving 
naevogenesis in different dermoscopic naevus subtypes.  
Since the mitogen-activated-protein-kinase (MAPK) pathway has the vast majority of point 
mutations in melanoma, targeted sequencing of genes such as BRAF and RAS (including NRAS, 
HRAS, and KRAS) have been the most commonly assessed genes in naevi1. However targeted 
sequencing of known driver mutations are limited to studying one or a few candidate genes. At the 
time of the study design, three genetically distinct naevi subgroups link NRAS with congenital 
melanocytic naevi (CMN), HRAS with Spitz naevi with a starburst pattern on dermoscopy, and 
GNAQ with blue naevi typified by a dermoscopically homogeneous blue pattern1. The benign and 
stable nature of Spitz and blue naevi have been postulated to be attributed to the non-existence of 
BRAF and NRAS mutations in these naevi types and alterations in HRAS and GNAQ not being key 
players in melanomagenesis1. No published study had comprehensively assessed acquired naevi in 
an unbiased way using next-generation sequencing methodologies such as whole exome sequencing 
(WES). Furthermore, besides Spitz ‘starburst pattern’ naevi and blue ‘homogeneous blue pattern’ 
naevi, studies that have assessed other dermoscopic subtypes of acquired naevi were limited to 
investigating BRAF status only2,3. The BRAF mutation had been shown to be prevalent in acquired 
naevi with the globular, reticular, mixed pattern with a peripheral rim of globules (PG), and mixed 
pattern with central globules/structureless area and peripheral network using a variety of 
methodologies; but had dissimilar results for reticular naevi2.  
This chapter focuses on a comprehensive discovery approach using WES to investigate the somatic 
mutational landscape present within globular, reticular and peripheral rim of globules patterned 
naevi (n=30) that have been shown to correspond to different microanatomical growth patterns2-4 
and are distinguished by their age of onset5,6, life cycle6 and relative melanoma risks4-6. The genetic 
profile of naevus tissue was ascertained by comparing this to the genomic DNA from saliva and 
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adjacent non-lesional skin. In the data presented in this chapter, there was mutually exclusive BRAF 
and NRAS mutation prevalence in all assessed dermoscopic subtypes of acquired naevi. The 
activation of the MAPK pathway in 100% of naevi samples was validated by performing targeted 
sequencing using the QX200 droplet digital™ PCR (ddPCR) system on a larger sample size (n=40) 
(see Chapter 3). Ultraviolet radiation (UVR)-related mutation signature was the dominant mutation 
signature in 97% of naevi, although there was a 93% and 30% prevalence of age-related and 
defective DNA repair-related signature respectively in the assessed naevi. In relation to 
dermoscopic patterns, the somatic mutation landscape of globular, reticular and PG naevi are 
characterised by differences in BRAF and NRAS prevalence and somatic mutation burden. Globular 
naevi was 92% BRAF V600E/K mutant and are associated with a higher somatic mutation burden. 
In particular globular naevi have a significantly higher proportion of T[C>T]A transitions that 
culminated in a greater proportion of ultraviolet radiation (UVR)-related mutation signature, but are 
largely genomically silent containing only minor copy number aberrations (CNAs). Reticular naevi 
were 67% BRAF V600E/K mutant and 33% NRAS mutant, whereas PG naevi were 100% BRAF 
V600E mutant and had a significantly higher proportion of C>G and T>A transversions. Reticular 
and PG naevi shared a significantly higher proportion of indels and large regional genome-wide 
CNAs, involving combined loss of melanoma-related tumour suppressor genes and oncogenes. 
These data satisfy Aim 1. 
 
Please note that a published version of this chapter7can be found in Appendix C. This chapter 
provides a more specific and in-depth analysis and discussion of key points specifically relevant 
to Aim 1 of this thesis.  
 
4.2 INTRODUCTION 
The malignant transformation of a naevus is rare in that approximately 70% of melanomas arise de 
novo whereas 30% (range 4-72%) of melanomas develop within a pre-existing naevus8. 
Investigation into the order of molecular events that contribute to the linear transformation and 
progression of melanocytic proliferations using a targeted gene approach describes TERT promoter 
mutations as early events in malignant transformation, and mutations and copy number aberrations 
absent in precursor melanocytic proliferations to be present in descendant neoplasms9. Moreover a 
mitogen-activated protein kinase (MAPK) signalling pathway mutation usually involving BRAF or 
NRAS is acquired early in melanocytic neoplasia, reiterating the role of the MAPK pathway in both 
the initiation and progression of melanocytic proliferations9.  
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Exome sequencing data of dysplastic naevi derived from patients with atypical naevus syndrome 
demonstrates a substantially lower mutational load, a different and lower frequency of ultraviolet-
associated mutational signature, as well as an absence of known melanoma driver mutations10. The 
genomically quiescent nature of these clinically atypical yet benign melanocytic proliferations in 
patients at high risk for melanoma provides early insight into the molecular rationale underpinning 
naevi stability. Nonetheless a gap exists in the molecular characterisation of acquired naevi with 
different dermoscopic patterns; corresponding to unique microanatomical growth patterns, time of 
onset, life cycle and relative melanoma risks. The unbiased discrimination of the somatic mutational 
profiles of these dermoscopic naevus subsets using next generation sequencing platforms will help 
to further elucidate the underlying molecular mechanisms of naevogenesis and processes that 
govern the senescent state of benign melanocytic proliferations.  
Using a comprehensive discovery approach, single-nucleotide variants (SNVs), mutational 
signatures, driver mutations and copy number aberrations (CNAs) in globular, reticular and 
peripheral rim of globules (PG) dermoscopic subtypes of acquired naevi was assessed by whole 
exome sequencing (WES). Targeted sequencing for TERT-promoter mutations was also carried out 
on the study samples. 
4.3 MATERIALS AND METHODS 
4.3.1 Tissue sampling and preparation 
With written informed consent, 30 acquired naevi with the globular (n=12; mean age 52.3 years), 
reticular (n=14; mean age 52.3 years) and PG (n=4; mean age 31.3 years) dermoscopic patterns 
identified from a database of prospectively imaged naevi11 were shave excised from 20 participants 
(17 male, 3 female; mean age 49.5 years). Ten participants (8 male, 2 female; mean age 49.4 years) 
each provided consent for two naevi to be shave excised (n=20) (See Chapter 3 Table 3). All naevi 
were located on intermittently sun-exposed body sites on the trunk and proximal extremities. Eight 
naevi (1 globular, 4 reticular and 3 PG naevi) were located on relatively less sun-exposed sites on 
the abdomen and posterior thighs whereas 22 naevi (11 globular, 10 reticular and 1 PG naevi) were 
located on relatively more sun-exposed sites on the back, chest, shoulders and dorsal arms. Each 
naevus was bisected and one half of the tissue was formalin-fixed and histopathologically 
diagnosed by a board certified pathologist and assessed according to a method adapted from 
Marchetti et al3. The second half of the tissue was dissected to isolate naevus from adjacent non-
lesional skin. The tissue was either flash frozen at -80°c (n=18) or preserved in RNAlater® 
(Thermo Fisher Scientific Inc, USA) prior to storage at -80°c (n=12). Some of the tissue samples 
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that were flash frozen at -80°c were subsequently treated with RNAlater®-ICE (Thermo Fisher 
Scientific Inc, USA) prior to DNA extraction (n=8). 
4.3.2 DNA extraction 
Tissue 
DNA extraction was performed either using the QIAamp DNA Mini Kit (QIAGEN, Hilden, 
Germany) (n=10) or the AllPrep DNA/RNA/miRNA Universal Kit (QIAGEN, Hilden, Germany) 
according to manufacturer’s protocol (n=20), amended according to sample size. The methods 
carried out are as described in Chapter 2 subsection 2.3.1.  
Saliva 
Saliva DNA samples were already available as the subjects were part of the NHMRC-funded 
project “Pigmentation genotypes and phenotypic correlations with dermoscopic naevus types and 
distribution”11,12. The methods carried out are as described in Chapter 2 subsection 2.3.1.  
4.3.3 Whole exome sequencing and next-generation sequencing data analysis 
DNA from matched saliva, naevi, and adjacent non-lesional skin were sent to fee-for-service 
provider Macrogen Inc (Seoul, Rep. of Korea) for exome library preparation (SureSelect V5+UTR; 
Agilent, CA, USA) and paired-end 100bp sequencing using the HiSeq4000 system (Illumina, CA, 
USA). Saliva-derived and tissue DNA were sequenced at a depth of ≥60x ≥100x on-target coverage 
respectively (or 100x or 200x raw coverage). All raw sequence reads (fastq) were analysed in-house 
using standard bioinformatic software run on the Translational Research Institute (TRI, Brisbane, 
Australia) high performance computing cluster. Please refer to Chapter 2 subsection 2.3.5 for 
further details.  
4.3.4 Somatic variant calling and filtering 
Somatic variants present in the naevi and adjacent non-lesional skin samples were determined by 
filtering out all variants that were present in the matching saliva-derived germline DNA followed 
by all variants that were present in 1000g2014oct_eur and ExAC NFE databases. Next, any variant 
present in a pool of 30 adjacent non-lesional skin samples were removed from each of the naevi 
samples which resulted in a list of somatic variants present only in the naevus tissue and not from 
adjacent non-lesional skin contamination. Please refer to Chapter 2 subsection 2.3.6 for further 
details. 
4.3.5 Detection of known mutations 
The Integrative Genome Viewer (IGV, Broad Institute) was first used to visualise the BAM files at 
specific codons in order to test the sensitivity of the exome sequencing depth for identifying 
somatic mutations in BRAF or NRAS present in the naevi. Next, the presence of the mutations was 
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validated in the stringently filtered dataset. Please refer to Chapter 2 subsection 2.3.7 for further 
details. 
4.3.6 Sanger sequencing of TERT promoter sequence  
The TERT promoter region was amplified using forward (5’- ACGAACGTGGCCAGCGGCAG-3’) 
and reverse (5’- CTCCCAGTGGATTCGCGGGC-3’) primer sequences designed using 
Primer3web (v4.0.0) software. The methods carried out are as described in Chapter 2 subsection 
2.3.4. 
4.3.7 Mutation signature analysis 
Filtered somatic SNVs present in the naevi and adjacent non-lesional skin were imported into the 
deconstructSigs13 package (https://github.com/raerose01/deconstructSigs). Mutation signatures 
were determined by using the framework of 30 COSMIC signatures 
(http://cancer.sanger.ac.uk/cosmic/signatures). Somatic mutations present in melanoma datasets 
were downloaded from 
ftp://ftp.sanger.ac.uk/pub/cancer/AlexandrovEtAl/somatic_mutation_data/Melanoma/. Please refer 
to Chapter 2 subsection 2.3.8 for further details. 
4.3.8 Copy number analysis 
Copy number aberrations were determined via the CNVkit14 package 
(https://github.com/etal/cnvkit) and run using Python 2.7. The matching adjacent non-lesional skin 
was used as the background normal. Please refer to Chapter 2 subsection 2.3.9 for further details. 
4.3.9 Statistical analysis 
Statistical analysis was performed using χ2 test, χ2 test for trend, two-tailed t-tests (Mann-Whitney), 
Fisher's exact test or Kruskal-Wallis test with GraphPad Prism version 7.03 for Windows (La Jolla, 
California, USA) or SPSS Statistics v.24 (IBM, USA). A p-value <0.05 was considered statistically 
significant. 
4.4 RESULTS  
4.4.1 Dermoscopic and histopathologic characteristics in naevi 
There were significant associations between dermoscopic pattern and histopathologic characteristics 
in the naevi subjected to WES (Table 4). A predominantly dermal growth pattern (n=12/12, 100%; 
p=0.0003) with absence of junctional melanocytes was associated with globular naevi (n=9/12, 
75%; p=0.0002). Conversely, junctional melanocytes were present in all of the assessed reticular 
and PG naevi, and small nests at the dermoepidermal junction were common (n=12/14, 86% and 
n=3/4, 75% respectively; p=0.0002). The distinguishing factor between the included reticular and 
PG naevi was that all PG naevi had small or large junctional nests, whereas a minority of reticular 
naevi had a lentiginous growth pattern without nests at the dermoepidermal junction (n=2/14, 14%). 
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There was largely an absence of architectural disorder and cytological atypia in globular (n=11/12, 
92%) and PG naevi (n=3/4, 75%), but this was present in reticular naevi (n=11/14, 79%; p=0.0011). 
4.4.2 Point mutation burden in naevi 
Somatic single-nucleotide variants (SNVs) were identified in all naevi from the exome pull-down 
region (coding and untranslated regions) with ranges from 30-668 mutations (median, 256) (Table 
2). The number of indels ranged from 8-92 (median, 25), and the proportion of indels ranged from 
4-41% (median, 10.5%). The total number of SNVs and indels ranged from 48-711 (median, 256), 
or 0-9 mutations per megabase (muts/Mb) of coding sequence (median, 3). The total number of 
deleterious mutations (nonsense and nonsynoymous) ranged from 13-340 SNVs (median, 89) and 
the proportion of deleterious mutations ranged from 16-49% (median, 35.5%).  
Globular naevi had the highest median for number of SNVs (p=0.0191), total SNVs and indels 
(p=0.0274), deleterious mutations (p=0.0333) and muts/Mb (p=0.0066); whilst reticular naevi had 
the highest median for number of indels (p=0.4545) amongst the dermoscopic naevus subtypes 
(Table 5). Interestingly deleterious mutations lost statistical significance whereas indels gained 
statistical significance when these two parameters were evaluated in the context of proportions 
rather than absolute counts across the dermoscopic patterns (p=0.0333 to 0.2399 and p=0.4545 to 
0.0083 respectively) (Table 5). The majority of globular and reticular naevi had a total number of 
SNVs and indels and muts/Mb equal to or greater than (≥) the observed median (Table 6; p=0.0445 
and p=0.0060 respectively). The differences in total number of SNVs and indels and muts/Mb 
between the dermoscopic patterns were statistically significant (Table 5 and Figure 7a-b; p=0.0274 
and p=0.0066 respectively). In particular there was a statistically significant difference between the 
total number of SNVs and indels and muts/Mb between globular and PG naevi (both p=0.0011). 
Although globular naevi had the highest proportion of deleterious mutations (median, 39%; Table 
5) and the majority of globular naevi had a proportion of deleterious mutations ≥ the observed 
median (n=8/12, 67%; Table 6), there was no significant difference in the proportion of deleterious 
mutations present between the dermoscopic patterns (Table 5 and Figure 7d; p=0.2399). 
Conversely, both reticular and PG naevi had a higher proportion of indels than globular naevi 
(Table 5), with the majority of reticular and PG naevi with a proportion of indels ≥ the observed 
median (n=10/14, 67% and n=3/4, 75%; p=0.0072) (Table 6). There was a statistically significant 
difference in the proportion of indels present between the dermoscopic patterns (Table 5 and Figure 
7c; p=0.0083). Even though PG naevi had a higher proportion of indels than reticular naevi, this did 
not reach statistical significance (median 24% vs. 16%; p=0.4229). 
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Table 4. Summary of the histopathologic characteristics of the 30 sampled globular, reticular and peripheral rim of globules dermoscopic 
naevus subtypes subjected to whole exome sequencing. The indicated p-value represents a χ2 test. 
 Total naevi Globular Reticular Peripheral Rim of Globules p-value 
Number of naevi 30 12 14 4  
Histopathologic subtype  
Junctional 7 (23) 0 (0) 6 (43) 1 (25) 0.0003 
Compound 14 (47) 3 (25) 8 (57) 3 (75) 
Intradermal 9 (30) 9 (75) 0 (0) 0 (0) 
Microanatomical growth pattern  
Predominantly or entirely epidermal 11 (37) 0 (0) 9 (64) 2 (50) 0.0001 
Equivalent epidermal and dermal components 4 (13) 0 (0) 2 (14) 2 (50) 
Predominantly or entirely dermal 15 (50) 12 (100) 3 (22) 0 (0) 
Nest formation of junctional melanocytes  
Absence of junctional melanocytes 9 (30) 9 (75) 0 (0) 0 (0) 0.0002 
Lentiginous growth pattern with absence of nests 3 (10) 1 (8) 2 (14) 0 (0) 
Combination of lentiginous growth and small nests 17 (57) 2 (17) 12 (86) 3 (75) 
Predominantly large junctional nests 1 (3) 0 (0) 0 (0) 1 (25) 
Architectural disorder and cytological atypia  
Absent 17 (57) 11 (92) 3 (21) 3 (75) 0.0011 
Present 13 (43) 1 (8) 11 (79) 1 (25) 
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Table 5. Summary of mutation burden characteristics (range and median) of the 30 sampled globular, reticular and peripheral rim of 
globules dermoscopic naevus subtypes subjected to whole exome sequencing. Prevalence of defective DNA repair signatures is presented in Table 
6. The indicated p-value represents a two-tailed Kruskal-Wallis t-test. 
Mutation Type All Naevi 
(n=30) 
Globular 
(n=12) 
Reticular 
(n=14) 
Peripheral Rim of 
Globules (n=4) 
p-value 
Range Median Range Median Range Median Range Median 
SNVs (count) 30-668 256 134-668 274.5 30-645 218 37-106 93 0.0191 
Indels (count) 8-92 25 11-92 24.5 8-66 27.5 8-49 20.5 0.4545 
SNVs and indels (count) 48-711 256 199-693 294.5 48-711 256 49-155 111.5 0.0274 
Deleterious mutations (count) 13-340 89 37-340 111.5 13-257 87.5 18-44 41.5 0.0333 
Muts/Mb 0-9 3 2-9 4 0-9 3 0-1 1 0.0066 
Indels (%) 4-41 10.5 2-41 5.5 5-41 16 8-32 24 0.0083 
Deleterious mutations (%) 16-49 35.5 16-49 39 24-43 35 28-41 35.5 0.2399 
Age-related signature 1 (%) 0-61 26 0-36 24 0-61 26.5 23-32 30 0.4281 
UVR-related signature 7 (%) 0-82 61 13-82 63.5 0-72 60 40-58 47 0.0861 
CNAs (count) 5-932 24.5 5-25 17.5 15-932 59 21-299 35 0.0007 
Abbreviations: SNVs, single-nucleotide variants; Muts/Mb, mutations per megabase; UVR, ultraviolet radiation; CNAs, copy number aberrations 
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Table 6. Summary of mutation burden characteristics (<median or ≥ median) and prevalence of defective DNA repair signatures of the 30 
sampled globular, reticular and peripheral rim of globules dermoscopic naevus subtypes subjected to whole exome sequencing. The indicated 
p-value represents a χ2 test for trend. 
 All Naevi Globular Reticular Peripheral Rim of Globules p-value 
Total naevi 30 12 14 4  
SNVs and Indels (count)  
< Median 256 14 (47) 4 (33) 6 (43) 4 (100) 0.0445 
≥ Median 256 16 (53) 8 (67) 8 (57) 0 (0) 
Muts/Mb  
< Median 3 11 (37) 2 (18) 5 (36) 4 (100) 0.0060 
≥ Median 3 19 (63) 10 (83) 9 (64) 0 (0) 
Indels (%)  
< Median 10.5 15 (50) 10 (83) 4 (29) 1 (25) 0.0072 
≥ Median 10.5 15 (50) 2 (17) 10 (71) 3 (75) 
Deleterious mutations (%)  
< Median 35.5 15 (50) 4 (33) 9 (64) 2 (50) 0.2827 
≥ Median 35.5 15 (50) 8 (67) 5 (36) 2 (50) 
Age-related signature 1 (%)  
Absence 2 1 (8) 1 (7) 0 (0) 0.2827* 
< Median 26 13 6 (50) 6 (43) 1 (25) 
≥ Median 26 15 5 (42) 7 (50) 3 (75) 
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Abbreviations: SNVs, single-nucleotide variants; Muts/Mb, mutations per megabase; UVR, ultraviolet radiation; CNAs, copy number aberrations 
*These p-values were derived from including ‘Absence’ under ‘<Median’ 
 
Table 6 continued… 
 All Naevi Globular Reticular Peripheral Rim of Globules p-value 
UVR-related signature 7 (%)  
Absence 1 0 (0) 1 (7) 0 (0) 0.0317* 
< Median 61 14 4 (33) 6 (43) 4 (100) 
≥ Median 61 15 8 (67) 7 (50) 0 (0) 
Defective DNA repair signatures  
Presence 10 4 (33) 3 (21) 3 (75) 0.3424 
Absence 20 8 (67) 11 (79) 1 (25) 
CNAs (count)  
< Median 24.5 15 11 (92) 3 (21) 1 (25) 0.0013 
≥ Median 24.5 15 1 (8) 11 (79) 3 (75) 
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4.4.3. Somatic single-nucleotide variant subclasses in naevi and adjacent non-lesional skin 
C>T transitions were the most prevalent SNV class in naevi (Figure 1a in the published version of 
this chapter7). In adjacent non-lesional skin, C>T transitions were again the most prevalent but this 
did not match the mutation profile observed in naevi (Figure 1d-e in the published version of this 
chapter7). When comparing the C>T transitions in a trinucleotide context, naevi was found to share 
many similarities with the mutation frequency distribution of cutaneous melanoma (Figure 1b in the 
published version of this chapter7). There was dominance of T[C>T]N and C[C>T]N particularly 
T[C>T]G and T[C>T]C (Figure 1b in the published version of this chapter7) though naevi and 
melanoma are distinct from adjacent non-lesional skin as this was characterized by dominance of 
A[C>T]G but low proportion of other C>T variants (Figure 1d in the published version of this 
chapter7). The discernible feature between naevi and melanoma is the higher ratio of 
Figure 7. Point mutation burden in the different dermoscopic subtypes of acquired naevi. 
There were statistically significant differences in the (a) number of SNVs and indels (b) 
mutations per megabase (c) and proportion of indels across globular, reticular and peripheral rim 
of globules naevi. (d) There was no significant difference in the proportion of deleterious 
mutations between the dermoscopic patterns (p=0.2399). 
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T[C>T]G:T[C>T]C in melanoma (Figure 1b in the published version of this chapter7). This increase 
in T[C>T]G transitions in the melanoma samples correspond to the presence of deleterious 
mutations in tumour suppressor genes such as ARID2, ATM, DCC, and NF1; all of which are absent 
in the sampled naevi all of which are absent in the sampled naevi and in naevi analysed by 
Melamed et al10. This supports the notion that loss of tumour suppressor gene function contributes 
to melanomagenesis. 
C>T transitions account for the majority of the variants observed across the three assessed 
dermoscopic naevus patterns (Figure 8). There was a higher proportion of C>T transitions in 
globular, over reticular and PG naevi (p=0.0575) though this was only statistically significant 
between globular and PG naevi (p=0.0198). Further evaluation of this base substitution in a 
trinucleotide context revealed globular naevi (with a primarily dermal component in this dataset) to 
have a significantly higher proportion of T[C>T]A transitions (p=0.0491) (Figure 9a); whereas 
G[C>T]T transitions approached near statistical significance in reticular naevi (p=0.0501) (Figure 
9b) (higher prevalence of architectural disorder and cytological atypia in this dataset). A higher 
proportion of T>G transversions was observed in reticular followed by PG and globular naevi 
(p=0.0732), yielding statistical significance between reticular and globular naevi (p=0.0206). There 
was a higher proportion of C>A transversions and T>C transitions in PG naevi when these variants 
were compared across the dermoscopic patterns, though this was not statistically significant 
(p=0.2461 and 0.0869 respectively). Nonetheless PG naevi had a significantly higher proportion of 
C>G and T>A transversions when these variants were compared across the dermoscopic patterns 
(p=0.0251 and 0.03 respectively) (Figure 8). Whilst there was no significant difference in the C>G 
and T>A transversions between reticular and PG naevi (p=0.2327 and 0.3817 respectively), there 
was a significantly higher proportion of these transversions in PG and reticular naevi respectively 
when both dermoscopic naevus subsets were compared to globular naevi (p=0.0132 and p=0.0234). 
Overall these data suggest that specific mutation types may contribute to the development of 
distinct dermoscopic and histopathologic naevus phenotypes.  
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Figure 8. Bar graph of the 6 SNV classes (C>A, C>G, C>T, T>A, T>C, and T>G) 
somatically observed in the different dermoscopic subtypes of acquired naevi.  
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4.4.4 Driver genes in naevi 
Using a combined gene-list from previous studies that have used a targeted-gene approach to 
identify likely causal genes in amongst a sea of passenger genes9,15, the number of melanoma driver 
genes that harboured a deleterious mutation that were present in the assessed naevi ranged from 1-
14 (Table S2 in the published version of this chapter7). Mutually exclusive mutations in BRAF and 
NRAS were the most frequent (83% or n=25/30 and 17% or n= 5/30 respectively) which is in 
keeping with the assessment using ddPCR (see Chapter 3). Other genes of note included MET with 
three mutations (10%; NM_000245: Glu266Lys, Pro712Thr, and Gly1151Arg), and GRIN2A with 
two mutations (7%; NM_000833: Arg899Trp and Pro1132Leu In addition to these well-known 
genes, we identified novel genes such as HDAC9 (NM_058176: p.Ser612Phe), MYH11 
(NM_002474:p.Gly743Glu), and DCC (NM_005215: p.Asp866Asn) which were flagged as 
Figure 9. Globular naevi have a significantly (p=0.0491) higher proportion of T[C>T]A 
transitions with a greater significance between globular and reticular naevi (p=0.0202).  
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predicted driver mutations using Intogen16 (Table S3 in the published version of this chapter7). 
Interestingly these novel ‘driver’ mutations are present at a similar mutation frequency as BRAF 
V600E and BRAF V600K respectively which indicate that they most likely occurred at the same 
time during naevus formation. In most cases where a BRAF mutation is present, other gene 
mutations are noted to co-occur at a similar mutation frequency (Tables S2 and S3 in the published 
version of this chapter7). However BRAF mutations was also noted to occur at a sub-clonal 
frequency (< % naevus cell estimate/naevus cellularity), and it is unclear if this is due to a late 
acquisition of the BRAF mutation or an observation of oncogene-induced senescence (OIS)17 in the 
initial naevus cell population followed by an outgrowth of cells that have acquired a selective 
advantage via a new mutation. Given that BRAF V600 mutations are the most prevalent, these are 
likely to be the initiator and the other genes that contain private deleterious mutations provide a 
permissive environment for naevus development. 
4.4.5 TERT promoter mutation in naevi 
There was absence of the non-coding mutation in TERT promoter in all assessed naevi (n=30). This 
includes naevi with and without architectural or cytological atypia (n=13 and 17 respectively). 
4.4.6 Mutation signatures in naevi and adjacent non-lesional skin 
The Catologue of Somatic Mutations in Cancer (COSMIC) mutational signatures based on analysis 
of 10952 exomes and 1048 whole genomes across 40 distinct types of human cancer reflect the 
different mutational processes that generate unique combinations of mutation types including the 
intrinsic slight infidelity of the DNA replication machinery, exogenous or endogenous mutagen 
exposures, enzymatic modification of DNA and defective DNA repair18. The profile of each of the 
30 mutational signatures is generated using the six classes of base substitution (C>A, C>G, C>T, 
T>A, T>C, T>G) with each substitution incorporating the bases immediately 5’ and 3’ to each 
mutated base and displayed based on the observed trinucleotide frequency19.  
It has been established that ultraviolet radiation (UVR) creates a well-known somatic mutation 
signature in cutaneous melanoma that is enriched with C>T transitions (signature 7)18. The 
predominance of C>T transitions observed in the assessed naevi (Figure 1 in the published version 
of this chapter7) resulted in a prevalent proportion of signature 7 related SNVs (97% or n=29/30; 
range 0-82%, median 61%; Figure 3a in the published version of this chapter7 and Table S4 in the 
published version of this chapter7). An age-related signature (signature 1), the result of endogenous 
spontaneous deamination of 5-methylcytosine also characterised by predominance of C>T 
transitions18 was the next most prevalent in naevi (93% or n=28/30; range 0-61%, median 26%; 
Figure 3a in the published version of this chapter7 and Table S4 in the published version of this 
chapter7). Remarkably, two naevi (1 globular, 1 reticular naevus) had no signature 1 and a low or 
absent signature 7 (13 and 0% respectively). Instead, evidence for defective DNA mismatch repair 
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associated with high numbers of small indels at mono/polynucleotide repeats18 was identified 
(signature 20; 23% and signature 6, 13% respectively). As these naevi are located in intermittently 
sun-exposed body sites, this highlights an alternative mechanism for naevi development besides 
UVR, especially considering the reticular naevus hypothesised to develop via the 
acquired/exogenous pathway of naevogenesis20 had absence of both signature 1 and 7. Defects in 
DNA repair associated with generation of indels was in fact prevalent in 30% (n=10/30) of the 
assessed naevi with many mutually exclusive signatures identified (signatures 3, 6, 15, 20, and 26)18 
(Figure 3a in the published version of this chapter7, Tables S1 and S4 in the published version of 
this chapter7), confirming that defective DNA repair contributes to naevogenesis.  
Signature 1 was prevalent in 92% globular (n=11/12), 93% reticular (n=13/14) and 100% PG naevi 
(n=4/4). PG naevi had a non-statistically significant higher signature 1 proportion (median 30%) 
than globular (median 24%) and reticular naevi (median 26.5%) (Table 5, p=0.4281), and the 
majority (n=3/4, 75%) of PG naevi had a signature 1 proportion that was ≥ the observed median 
(Table 6, p=0.5134). There was no significant association between signature 1 and the age at 
sampling of naevi (data not shown), however interestingly the participants that donated the PG 
naevi in this dataset was younger (mean age 31.3 years) than the participants that donated globular 
and reticular naevi (mean age 52.3 years for both).  
Signature 7 was prevalent in 100% globular (n=12/12) and PG naevi (n=4/4) and 93% (n=13/14) 
reticular naevi. Globular naevi had a non-statistically significant higher signature 7 proportion 
(median 63.5%) than reticular (median 60%) and PG naevi (median 47%) (Table 5, p=0.0861), 
where 67% (n=8/12) globular and 50% (n=7/14) reticular naevi had a signature 7 proportion that 
was ≥ the observed median whereas 100% (n=4/4) PG naevi had a signature 7 proportion that was 
less than (<) the observed median (Table 6, p=0.0317). It is likely that the PG naevi had a signature 
7 proportion < the observed median due to the majority of these naevi also being located on 
relatively less sun-exposed sites (n=3/4, 75%) as compared to the globular (n=1/12, 8%) and 
reticular naevi (n=4/14, 29%). Defective DNA repair signatures were more prevalent in PG naevi 
(n=3/4, 75%), whereas this was largely absent in globular (n= 8/12, 67%) and reticular naevi 
(n=11/14, 79%; p=0.3424) (Table 6). Moreover, a defective DNA repair signature was absent in 
87.5% (n=7/8) globular and 100% (n=7/7) reticular naevi that have a signature 7 proportion ≥ the 
observed median, whereas a defective DNA repair signature was present in the majority of globular 
and PG naevi that had a signature 7 proportion < the observed median (both 75% or n=3/4 
respectively; p=0.014). Notably, a PG naevus without a defective DNA repair signature was located 
in a relatively more sun-exposed site on the dorsal arm and had the highest proportion of signature 7 
(58%) amongst the PG naevi. A defective DNA repair signature was absent in the majority reticular 
naevi that had a signature 7 profile that was < the observed median (57% or n=4/7).  
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In the adjacent non-lesional skin, there was also a predominance of C>T transitions (see Figure 1 in 
the published version of this chapter7) although this only resulted in UVR-related signature 7 in a 
minority of samples (10% or n=3/30; range 0-17%, median 0%) (Figure 3b in the published version 
of this chapter7). Defective DNA repair signatures (signatures 3 and 26)18 were however frequently 
observed (83% or n=25/30; range 0-22%, median 13% and 50% or n=15/30; range 0-14%, median 
0% respectively) along with age-related signature 1 (100% or n=30/30; range 21-45%, median 
32%).  
4.4.7 Point mutation burden and mutation signatures in naevi relative to degree of sun 
exposure 
Naevi on relatively more sun-exposed sites (n=22/30; 11/22 globular, 10/22 reticular and 1/22 PG 
naevi) had a significantly higher proportion of UVR-related signature 7 mutations (median 62.5% 
vs. 42%; p=0.0069) (Figure 10b) which is consistent with UVR contributing to high somatic 
mutation burden; reflected in these naevi having significantly higher number of SNVs and indels 
(median 279.5 vs. 73; p=0.0004), muts/Mb (median 3.5 vs. 1; p=0.0002) (Figure 10a) and a higher 
proportion of deleterious mutations (median 36.5% vs. 30.5%; p=0.0574) (Figure 10d). Naevi on 
relatively less sun-exposed body sites (n=8/30; 1/8 globular, 4/8 reticular, 3/8 PG naevi) had a 
significantly higher proportion of indels (median 26.5% vs. 9%; p=0.0095) (Figure 10c) and a 
higher prevalence of defective DNA repair signatures than naevi on relatively more sun-exposed 
sites (75% or n=6/8 vs. 18% or n=4/22), although this observation could also be explained by the 
predominance of reticular (n=4/8) and PG naevi (n=3/8) than globular naevi (n=1/8) in these 
relatively less sun-exposed body locations - dermoscopic naevus subtypes observed herein to have a 
significantly higher proportion of indels as compared to globular naevi.  
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4.4.8 Copy number aberrations in naevi 
Cutaneous melanomas have an increased amount of copy number aberrations (CNAs) in addition to 
a high somatic mutation burden. Melanomas often have focal deletions in tumour suppressor genes 
(e.g. CDK2NA), focal amplifications in oncogenes (e.g. MITF), and extensive regions of copy 
number loss-of-heterozygosity (LOH) often encompassing whole chromosomal arms21. Complex 
genomic rearrangements are also the hallmark of non-UVR induced mucosal and acral 
melanomas22. Copy number aberrations were identified in the assessed naevi, ranging from 5-932 
(median, 24.5). Reticular (median, 59) and PG naevi (median, 35) have a higher number of CNAs 
than globular naevi (median, 17.5) (Table 5, p=0.0007). The majority of reticular (n=11/14, 79%) 
Figure 10. Somatic mutation type and mutation signature of naevi relative to degree of sun-
exposure on intermittently sun-exposed sites. Naevi located on relatively more sun-exposed 
sites are more likely to have a significantly higher (a) mutations per megabase (p=0.0002), (b) 
proportion of ultraviolet radiation-related signature 7 (p=0.0069), and (d) deleterious mutations 
(p=0.0574); in contrast to indels that are more prevalent in naevi located on relatively less sun-
exposed sites (p=0.0095).  
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and PG naevi (n=3/4, 75%) had number of CNAs ≥ the observed median whereas 92% (n=11/12) 
globular naevi had number of CNAs < observed median (Table 6, p=0.0013). Globular naevi were 
largely genomically silent containing only minor CNAs (Figure 11a). However there was a high 
frequency of genome-wide CNAs in reticular and PG naevi (p<0.0001; Figure 11b and 11c; Table 
S6-S7 in the published version of this chapter7) which correlates with the higher proportion of 
observed indels in these dermoscopic naevi subtypes. The extensive nature of the CNAs in the 
reticular/PG naevi would lead one to assume that this may indicate the inception of 
melanomagenesis, however, upon closer inspection of the genes involved, the CNAs appear to be 
balanced events. The majority of the observed CNAs were large regional CNAs (mainly LOH) 
concurrently involving key melanoma-related tumour suppressors and oncogenes (Figures S1 and 
S2 in the published version of this chapter7), rather than focal regions of loss which is a hallmark of 
cutaneous melanoma. These large regional events suggest that no specific gene is being targeted; 
instead this is a random mutagenic process. To find evidence for LOH events effecting gene 
expression, interrogation of the melanoma TCGA data23 revealed that on average, LOH of key 
melanoma genes can significantly result in a loss of expression in tumour suppressors as well as in 
oncogenes (Figure S1 and S2 in the published versions of this chapter7). Therefore it is postulated 
that the net effect of the combined loss of both gene functions in the same naevus to have an overall 
copy neutral effect, thus keeping the naevus in a state of equilibrium so as to be ‘protected’ against 
malignant transformation. 
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4.5 DISCUSSION 
We herein demonstrate the mutational repertoire of acquired naevi including globular, reticular and 
PG dermoscopic subtypes using whole exome sequencing. The findings confirm mutually exclusive 
BRAF and NRAS mutations together with a wide range of somatic mutations (30-668 mutations) or 
0-9 muts/Mb. Other driver genes detected at a lower prevalence to BRAF V600 include the 
melanoma-associated genes (e.g. GRIN2A) and novel genes (e.g. HDAC9, MYH11 and DCC) 
present as similar mutation frequency to BRAF V600E and BRAF V600K. C>T transitions were 
confirmed to be the most prevalent SNV class and overall the analysed naevi share many 
similarities to the mutation frequency distribution in cutaneous melanoma. Notably, there was a 
prevalent proportion of UVR-related (97%), age-related (93%) and defective DNA repair-related 
signatures (30%). Based upon these findings, this study has identified some novel mechanisms 
which contribute to naevogenesis. In relation to dermoscopic patterns, mutational signature analysis 
identified globular naevi to have a significantly higher proportion of T[C>T]A transitions; but 
overall globular naevi are largely genomically silent containing only minor CNAs. Reticular and 
PG naevi were more likely to have a higher proportion of indels and genome-wide CNAs, whilst a 
significantly higher proportion of C>G and T>A transversions was also observed in PG naevi. The 
genomic landscape of naevi based on dermoscopic pattern using next generation sequencing 
platforms has never been reported. 
The data confirms a low somatic mutation burden in the naevi (3 muts/Mb) in comparison to other 
UVR-associated cutaneous malignancies such as cutaneous melanoma (38.2 muts/Mb)22, primary 
cutaneous squamous cell carcinoma (SCC) (33.3 muts/Mb)24 and metastatic cutaneous SCC (33 
muts/Mb)25. The total number of deleterious mutations (nonsense and nonsynonymous) identified in 
the assessed naevi (range 13-340; median, 89) is higher than those previously described in the study 
Figure 11. Copy number aberrations (CNAs) in different dermoscopic subtypes of 
acquired naevi. Genome-wide copy number aberrations (CNAs) in globular, reticular and 
peripheral rim of globules (PG) dermoscopic subtypes of acquired naevi. Globular naevi are 
largely genomically silent with minor CNAs observed and reticular PG naevi have significantly 
(p<0.0001) more CNAs with mostly large regional LOH events being present. Chromosomes are 
represented from left to right in chromosomal order. Dark blue = copy number equivalent to 
homozygous deletion (HD or deep deletion); Light purple = copy number equivalent to loss of 
heterozygosity (LOH or shallow deletion); Light red = copy number equivalent to ≥1 copy 
(gain); and Dark red = copy number equivalent to ≥3 copies (amplified). 
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of 19 naevi (range 0-46; median, 19) comprised of dysplastic naevi (n=11), congenital naevi (n=2) 
and acquired naevi (n=6) derived from individuals with atypical naevus syndrome by Melamed et 
al10. These samples by Melamed et al demonstrated a substantially lower mutational load than 
cutaneous melanoma and a different and lower frequency of UVR-associated mutational signature, 
together with an absence of known melanoma driver mutations10. The observed differences are 
likely due to the difference in sample populations with the naevi herein derived from a population 
that have a history of frequent sun exposure combined with a geographical region that has one of 
the highest level of UVR in the world (Brisbane, Australia). However, the discovery that two naevi 
had no signature 1 and a low or absent signature 7 but had evidence for defective DNA mismatch 
repair highlights an alternative mechanism for naevi development besides UVR.  
C>T transition was also the dominant base substitution in adjacent non-lesional skin, although this 
only culminated to a UVR-related mutation signature in 10% of adjacent non-lesional skin. The 
mutation profile between naevi and adjacent non-lesional skin in comparison with somatic 
mutations present in melanoma datasets reveals similarities between the C>T mutation frequency 
distribution of naevi and cutaneous melanoma and that was different to adjacent non-lesional skin. 
Remarkably, defective DNA repair signatures were more frequently observed in adjacent non-
lesional skin than in the assessed naevi, in addition to 100% age-related mutation signature 
prevalence. The skin adjacent to the naevus is primarily composed of keratinocytes and 
melanocytes and it is not possible to determine precisely where these signatures derive from 
without single-cell sequencing. Nevertheless, these data challenges the perception of UVR being a 
dominant pathogenic factor in naevogenesis9 but suggests that the accumulation of age-related 
mutations and defective DNA repair machinery in a given melanocyte lead to the accumulation of 
UVR-related mutations that contribute to naevogenesis. The overall absence of the classical UVR 
signature mutations in the adjacent non-lesional skin which predominates in the more melanin-
containing naevi, suggests that the melanin content may contribute to the excess of C>T transitions 
specific to the UVR signature. This notion is supported by the study by Premi et al.26 which 
described that many of cyclobutane pyrimidine dimers (CPDs) arise via the breakdown of melanin.  
Naevogenesis is also genetically pre-determined as total naevus count is a highly heritable trait, 
with twin studies estimating that approximately 60 to 70% can be explained by genetic factors27-29. 
Polymorphisms within four genes IRF4, MTAP, PLA2G6 and MITF have been shown to strongly 
influence total naevus count. A single polymorphism within an intronic region of the IRF4 gene, 
rs12203592*C/T, shows a strong genotype-by-age interaction on naevus count30, and also plays a 
major influence on pigmentation traits31, tyrosinase expression and INFg-induced gene 
regulation31,32. An association between total naevus count and single nucleotide polymorphisms 
(SNPs) upstream of the MTAP gene, adjacent to the well-known tumour suppressor 
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gene CDKN2A on chromosome 9p21, and the PLA2G6 gene on chromosome 22q13 have also been 
reported33. These 3 genes were used to examine associations with cutaneous melanoma risk across 
body site and histological subtype in a case-control comparison34. The fourth gene, MITF, has a 
coding region E318K allele that has also been shown to have a significant effect on naevus count, 
pigmentation and melanomagenesis12,35,36. New naevus-associated genes have been recognized 
from a meta-analysis of 11 naevus genome-wide association study (GWAS) from Australia, 
Netherlands, UK and USA comprising over 50,000 phenotyped individuals37. This confirms that the 
strongest total naevus count-associated SNPs are within the IRF4, MTAP, and PLA2G6 genes, and 
has detected new loci at or near genome-wide level of significance. Using candidate analysis 
of MC1R variant alleles and 85 other genes38, several loci were associated with dermoscopic 
patterns seen during childhood, supporting the idea that genetic factors will strongly influence 
naevus morphology as well as total naevus count in adults37. 
Although C>T transition was the most prevalent base substitution across all assessed naevi, the 
differences in the mutation frequency of C>T (e.g. higher C>T transition between globular and PG 
naevi), C>T within a trinucleotide context (e.g. significantly higher proportion of T[C>T]A in 
globular naevi, higher proportion of G[C>T]T transition that approached statistical significance in 
reticular naevi), and other types of base substitutions (e.g. significantly higher proportion of C>G 
and T>A  transversions  in PG naevi) in different dermoscopic patterns suggests that specific 
mutation types may contribute to the development of distinct dermoscopic and histopathologic 
naevus phenotypes. However it is also important to consider that other factors such as naevi onset, 
and the age of the individuals from which these naevi were derived from, may account for the 
somatic mutation differences seen between dermoscopic patterns as there are significant age-related 
differences in the onset of globular (childhood), reticular (puberty and adulthood) and PG naevi 
(puberty or early adolescence). Based on this, it would be fair to assume that the globular naevi in 
this dataset would have been present for a much longer period of time in a study population with a 
mean age of 52.3 years in comparison to the PG naevi in a study population with a mean age of 
31.3 years.  
Globular naevi that are characterised by a dermal growth pattern, largely absent architectural 
disorder or cytological atypia and high naevus cell density in this dataset was associated with a 
higher somatic mutation burden that culminated in a greater proportion of UVR-related mutation 
signature. The UVR-related mutation signature observed in globular naevi that is more pronounced 
than reticular and PG naevi may relate to the early onset of this naevus type during childhood and 
persistence into adulthood, thus resulting in accumulation of somatic mutations in a time-dependent 
manner – implying that naevus age determines the proportion of UVR signature in naevi. The minor 
CNAs in globular naevi may play a role in the stable life cycle and lifelong persistence of this 
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naevus, although globular naevi have been postulated as melanoma precursors (albeit the risk still 
being low)4 due to naevi found to co-exist in histopathologic contiguity with melanoma typically 
have dermal components39-44. In theory, the continued accumulation of UVR-related mutagens in a 
melanocytic proliferation that has lifelong persistence contributes to a favourable environment for 
malignant transformation, although it stands to reason that melanomagenesis requires other 
mutational processes besides UVR-mutation signature.  
Reticular and PG naevi with an epidermal growth pattern typically characterised by junctional nests 
in this dataset had a significantly higher proportion of indels and genome-wide CNAs involving 
combined loss of melanoma-related tumour suppressor genes and oncogenes. The indels in the PG 
naevi is possibly a manifestation of the higher proportion of age-related signature and a higher 
prevalence of defective DNA repair mutation signatures. As focal regions of loss of tumour 
suppressor gene is a hallmark of cutaneous melanoma, the genome-wide CNAs with balanced copy 
number events in reticular and PG naevi keeps these naevi in a state of equilibrium. Further to this, 
the large regional CNAs may help to reason out the evolution and fate shared by reticular and PG 
naevi20. It has been observed that once optimal growth has been achieved, PG naevi lose their rim 
of globules as the larger peripheral junctional nests extend horizontally to manifest either a reticular 
pattern (e.g. reticular naevus), or a mixed pattern with central globules/structureless area with a 
peripheral network; followed by involution20. Reticular naevi also eventually involute, possibly via 
transepidermal elimination of apoptotic cells4,20. This documented life cycle of reticular and PG 
naevi indicate reticular naevi to represent a later phase whilst PG naevi to represent an earlier phase, 
such that possibly a subset of BRAF V600E mutant reticular naevi may have had the transient 
peripheral rim of globules during the growth phase (e.g PG naevus). The presence of architectural 
disorder or cytological atypia in clinically benign reticular naevi in this dataset may be due to 
previous migration and/or proliferation of the naevocytes in and between the dermal and epidermal 
compartments, rather than a red herring. This benignancy of all analysed naevi is supported by the 
absence of TERT promoter mutations, as this have been reported as early events in malignant 
transformation9. Stratification of the naevi into dermoscopic patterns, and the dermoscopic naevus 
subtypes included in this study demonstrating statistically significant differences in histopathologic 
features to one another, represent strengths of this study. The limitations include a small sample size 
particularly that of PG naevi, and next-generation sequencing artefacts may also occur.  
4.6 CONCLUSION 
In conclusion, the somatic mutational landscape of dermoscopic naevus subsets distinguishes some 
of the molecular hallmarks of naevi in relation to melanoma. The constellation of somatic events 
and mutational processes highlights that in most cases, acquired naevi occur following cumulative 
exposure to UVR together with defective DNA repair mechanisms in normal skin melanocytes. 
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This environment permits the accumulation of UV-related somatic mutations evident in the 
mutation signatures observed in the naevi and adjacent non-lesional skin. Copy number aberration 
events that are absent or balanced in clonally expanded melanocytes are predicted to lead to 
naevogenesis (Figure 6 in the published version of this chapter7). In contrast, if these CNA events 
become imbalanced in a given clonal expansion of melanocytes, then this contributes to the 
formation of early melanomas (Figure 6 in the published version of this chapter7). The genomic 
profile of distinct dermoscopic naevus subsets provides insights into the underlying mechanisms 
that influence their evolution and life cycle, and suggest specific mutation types may contribute to 
the development of distinct naevus phenotypes. Exome sequencing on a larger number of PG naevi 
would have been ideal. Single-cell RNA-seq technology (e.g. chromium single cell 3’ solution) and 
further protein studies would help to elucidate the significance of these somatic mutations in 
changing gene expression and protein functionality and its contribution to naevus phenotype and 
behaviour. 
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CHAPTER 5 
Genotype of naevus tissue in comparison with cultured 
naevocytes provides evidence that some acquired naevi 
contain polyclonal cell populations 
5.1 RELEVANCE OF THESIS AIMS 
This chapter relates to thesis aim 3.  
Aim 3: Compare and contrast the genotype of different dermoscopic naevus subtypes with 
histopathologic features through characterisation of cultured naevocytes. 
At the time of the study design, a study that employed Sanger sequencing and ultradeep 
pyrosequencing (UDPS) to compare the BRAF prevalence in different dermoscopic subtypes of 
acquired naevi including globular, reticular and peripheral rim of globules (PG) naevi detected 
polyclonal BRAF mutations in reticular and PG naevi via the UDPS method1. This finding supports 
the theory that naevi are not always clonal cell populations, but can be polyclonal. The presence of 
concurrent NRAS mutations in the NRAS mutant naevi determined via droplet digital™ PCR 
(ddPCR) (see Chapter 3) also supports this notion.  
This chapter seeks to assess the ‘clonality’ of different dermoscopic naevus subtypes by correlating 
the genotype and histopathologic features with the propagation of naevi in cell culture experiments, 
as well as by comparing the somatic variants present between naevus tissue and adjacent non-
lesional skin tissue together with matching cultured melanocytes. Based upon the QX200 droplet 
digital™ PCR (ddPCR) system (see Chapter 3), the majority of the naevi subjected to cell culture 
were BRAF V600E mutant (n=15/17), although the BRAF V600K (n=1/17) and NRAS (n=1/17) 
mutation were also detected. In the data presented in this chapter, the successfully cultured naevi 
(n=6/17) were BRAF V600E (c.1799T>A) or BRAF V600K mutant reticular and PG naevi with nest 
formation of junctional melanocytes on histopathology. The DNA extracted from a BRAF V600E 
(c.1799T>A) PG naevus did not meet the criteria for WES. Globular naevi that had a predominantly 
dermal growth pattern which corresponded to a higher percentage naevus cell density (naevus 
cellularity) on histopathology and a higher BRAF V600E fractional abundance (FA) did not 
propagate in culture (n=8/8). Upon whole exome sequencing (WES), there was an approximately 3 
to 4 fold higher BRAF V600E (c.1799T>A) mutant frequency in the cultured naevocytes as 
compared to naevus tissue in 2/5 paired naevi. The BRAF V600E mutation was present in naevus 
tissue but absent in cultured naevocytes in 2/5 naevi, whereas 1/5 naevi had the same BRAF V600K 
mutant frequency in naevus tissue and cultured naevocytes. Notably, the majority of somatic 
mutations detected in the cultured naevocytes were absent in naevus tissue in all of the successfully 
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cultured and sequenced naevi. Given that a different portion of the naevus was subjected to culture 
as compared to the naevus tissue that was sequenced, the intratumoral heterogeneity provides 
evidence for the presence of polyclonal cell populations in naevi. These data satisfy Aim 3. 
5.2 INTRODUCTION 
Naevi have been considered clonal cell populations originating from a single initiating naevocyte2. 
This proposition is based upon the presence of the BRAF V600E mutation in all cells of assessed 
naevi (n=10), and as such the BRAF V600E mutation is an early initiating event that drives clonal 
expansion2. An alternate to this is the theory that naevi are not always clonal but can be polyclonal, 
based upon findings that suggest that naevi are multicellular in origin resulting from random 
proliferation of cells containing wild-type BRAF as well as cells containing mutant BRAF and are 
therefore senescent multiclonal pool of melanocytes that have acquired an oncogenic BRAF 
mutation3.  
To explore the ‘clonality’ of freshly acquired naevi specimens, different dermoscopic subtypes of 
acquired naevi were collected from study participants and dissected for cell culture experiments. 
The shared somatic variants between naevus tissue and adjacent non-lesional skin tissue together 
with matching cell cultures was then investigated using whole exome sequencing (WES).   
5.3 MATERIALS AND METHODS 
5.3.1 Tissue sampling and preparation 
With written informed consent, 17 acquired naevi with the globular (n=8), reticular (n=5) and a 
peripheral rim of globules (PG) (n=4) dermoscopic patterns were shave excised from 12 
participants (8 male, 4 female; mean age 46.3 years). Five participants (4 male, 1 female; mean age 
51.4 years) each provided consent for two naevi to be shave excised (n=10). Each naevus was 
bisected and one half of the tissue was formalin-fixed and histopathologically diagnosed by a board 
certified pathologist and assessed according to a method adapted from Marchetti et al4. The naevus 
cellularity (percentage naevus cell density) was also estimated histopathologically. The second half 
of the tissue was further bisected where a quarter was retained for genomic work-up and a quarter 
dissected for cell culture experiments. Each quarter was dissected to isolate the naevus from 
adjacent non-lesional skin. The quartered tissue sample for genomic work-up was either flash 
frozen at -80°c (n=9) or preserved in RNAlater® (Thermo Fisher Scientific Inc, USA) prior to 
storage at -80°c (n=8). Some of the tissue samples that were flash frozen at -80°c were subsequently 
treated with RNAlater®-ICE (Thermo Fisher Scientific Inc, USA) prior to DNA extraction (n=7).  
5.3.2 Primary cell culture 
Matched naevus and adjacent non-lesional skin (n=17) were subjected to cell culture using an 
adapted protocol described previously5,6 based on methods described by Soo et al7,8 and McNeal et 
al9. Please refer to Chapter 2 section 2.4 for further details. 
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5.3.3 DNA extraction 
Tissue 
DNA extraction was performed on all matched naevus tissue and adjacent non-lesional skin tissue 
of samples subjected to cell culture (n=17). A subset of matched naevus and adjacent non-lesional 
skin (n=2) was performed using the QIAGEN QIAamp DNA Mini Kit (QIAGEN, Hilden, 
Germany) according to manufacturer’s protocol. In the other matched naevus and adjacent non-
lesional tissue (n=15), co-extraction for DNA, RNA and miRNA was performed using the 
QIAGEN AllPrep DNA/RNA/miRNA Universal Kit (QIAGEN, Hilden, Germany) according to 
manufacturer’s protocol and amended according to sample size. The methods carried out are as 
described in Chapter 2 subsection 2.3.1. 
Saliva 
Saliva DNA samples were already available as the participants were part of the “Pigmentation 
genotypes and phenotypic correlations with dermoscopic naevus types and distribution”10,11, The 
methods carried out are as described in Chapter 2 subsection 2.3.1.   
Cultured cells 
DNA extraction was performed on cultured naevocytes (n=9) and the adjacent non-lesional skin 
cells (n=12) (Table 1) using the QIAGEN QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) 
according to manufacturer’s protocol. Please refer to Chapter 2 subsection 2.3.1 for further details. 
The DNA extracted from five matched naevus and adjacent non-lesional skin cultured cells (Table 
7) was adequate for WES and the remaining samples will be used for future validation of candidate 
genes. 
5.3.4 Droplet digital™  PCR  
Mutation detection was performed on the extracted DNA samples using the QX200 ddPCR system. 
The methods carried out are as described in Chapter 2 subsection 2.3.3. 
5.3.5 Whole exome sequencing and PCR analysis 
Matched specimens consisting of naevus (n=5), adjacent non-lesional skin, cultured cells and saliva 
samples were sent to the FFS provider MacroGen, Inc (Seoul, Republic of Korea) for WES. All 
exome libraries (Agilent Sure Select V5 +UTR) were sequenced at a depth of up to 200x raw 
sequence reads/coverage using 100bp PE sequencing on the Illumina HiSeq4000 platform to 
generate approximately 100x on target sequence. All raw sequence reads (fastq) were analysed in-
house using standard bioinformatic software run on the Translational Research Institute (TRI, 
Brisbane, Australia) high performance computing cluster. Please refer to Chapter 2 subsection 2.3.5 
for further details. 
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Table 7. Samples subjected to cell culture. 
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) Culture Extraction WES 
Naevus Non-
lesional 
Skin 
Naevus Non-
lesional 
Skin 
G
lo
bu
la
r 
39RB 6 5x4 60 Chest M I 3 0 0 80 - - L-R24C DNA 
PL-R24C 
DNA × 
52JH 40 6x5 60 Back F I 3 0 0 80 - 
1 X PL-
EV 
Frozen, 5 
X PL-
R24C 
Frozen 
L-EV 
DNA, L-
R24C 
DNA 
PL-EV 
DNA, PL-
R24C 
DNA/RNA 
× 
61JB 115 8x5 66 Back M C 3 1 0 60 - - - - N/A 
61JB 133 9x5 66 Back M I 3 0 0 50 - - - - N/A 
111CM 3 8x6 35 Neck M I 3 0 0 70 - 
1 X PL-
R24C 
Frozen 
- PL-R24C DNA × 
111CM 21 7x7 35 Back M I 3 0 0 60-70 - - - - × 
158RP 4 6x7 65 Ext M I 3 0 0 60-70 - 
1 X PL-
R24C 
Frozen 
- PL-R24C DNA × 
510AN 
 
2 
 6x8 65 Ext M I 3 0 0 70 - 
1 X PL-
R24C 
Frozen 
- PL-R24C DNA × 
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158RP 78 6x4 65 Ext M J 1 2 1 <5 
3 X L-
R24C 
Frozen 
2 X PL-
R24C 
Frozen 
L-R24C 
DNA/R
NA, L-
R24C 
Protein 
PL-R24C 
DNA/RNA, 
PL-R24C 
Protein 
√ 
510AN 23 9x5 65 Abdo M C 1 1 0 <5 
2 X L-
R24C 
Frozen 
1 X PL-
R24C 
Frozen 
L-R24C 
DNA/R
NA, L-
R24C 
Protein 
PL-R24C 
DNA/RNA, 
PL-R24C 
Protein 
√ 
1346KJ 7 8x5 38 Back F C 2 2 0 10 
1 X L-
R24C 
Frozen 
1 X PL-
R24C 
Frozen 
L-R24C 
DNA/R
NA, L-
R24C 
Protein 
PL-R24C 
DNA/RNA, 
PL-R24C 
Protein 
√ 
695MB 59 8x10 28 Ext M C 2 2 1 10 
1 X L-
R24C 
Frozen 
3 X PL-
EV, 3 X 
PL-R24C 
Frozen 
L-R24C 
DNA/R
NA, L-
R24C 
Protein 
PL-EV 
DNA/RNA, 
PL-R24C 
DNA/RNA, 
PL-R24C 
Protein 
√ 
903JA 33 3x3 54 Back M J 1 2 1 <1 - 3 X PL-EV Frozen 
L-R24C 
DNA 
PL-EV 
DNA × 
Pe
ri
ph
er
al
 R
im
 o
f 
G
lo
bu
le
s 
822MT 10 12x9 26 Abdo F C 2 2 0 30 
2 X L-
R24C 
Frozen 
- L-R24C DNA - √ 
1030NW 28 2x3 26 Back F C 3 2 0 10 
2 X L-
R24C 
Frozen 
- L-R24C DNA 
PL-EV 
DNA × 
1030NW 54 4x2 26 Back F J 1 3 0 5 - - - - N/A 
1062DM 76 6x5 33 Abdo M C 1 2 1 20 - 2 X PL-EV Frozen - 
PL-EV 
DNA, PL-
R24C DNA 
× 
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Microanatomical growth pattern; 1 = predominantly or entirely epidermal, 2 = equivalent epidermal and dermal components, 3 = predominantly or 
entirely dermal 
Nest formation of junctional melanocytes; 0 = absence of junctional melanocytes, 1 = lentiginous growth pattern with absence of nests, 2 = 
combination of lentiginous growth and small nests, 3 = predominantly large junctional nests 
Architectural disorder and cytological atypia; 0 = absent, 1 = present 
Whole exome sequencing (WES) status; √ = yes, × = no, N/A = not applicable
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5.3.6 Sanger sequencing 
Sanger sequencing via PCR of BRAF exon 15 was performed using the forward primer sequence 5’- 
TCATAATGCTTGCTCTGATAGGA-3’ and the reverse primer sequence 5’-
GGCCAAAAATTTAATCAGTGGA-3’. The methods carried out are as described in Chapter 2 
subsection 2.3.4. 
5.3.7 Bioinformatics 
All sequences reads were aligned to the human (hg19) reference genome using the BWA 
alignment12 program. PCR duplicates were marked using Picard13, aligned reads were recalibrated 
using GATK14, variants were called using GATK and Samtools12 and annotated using 
ANNOVAR15. Somatic mutations present in the naevus tissue and cultured naevocytes were 
discovered following the removal of the germline mutation component (saliva-DNA derived). The 
background somatic mutations, present in normal sun-exposed skin, were filtered out using the 
somatic mutations observed in the adjacent non-lesional skin tissue and cultured cells. The somatic 
mutations present in cultured naevocytes only (and absent in naevus tissue) were established by 
removing the somatic mutations shared by both cultured naevocytes and naevus tissue. 
5.3.8 Statistical analysis 
Statistical analysis was performed using χ2 test, χ2 test for trend or Fisher’s exact test with Graph-
Pad Prism version 7.03 for Windows (La Jolla, CA, U.S.A.). A p-value <0.05 was considered 
statistically significant.  
5.4 RESULTS  
5.4.1 Genotype and phenotype of cultured naevi  
There were significant associations between dermoscopic pattern and histopathological 
characteristics in the naevi subjected to cell culture experiments (Table 8).  
A predominantly dermal growth pattern (n=8/8, 100%) with absence of junctional melanocytes was 
associated with globular naevi (n=7/8, 88%; p=0.0074). Conversely, a predominantly epidermal 
growth pattern was associated with reticular (n=3/5, 60%) and PG naevi (n=2/4, 50%; p=0.0071). 
Lentiginous growth and small nests was equivocal in both reticular and PG naevi (n=4/5, 80% and 
n=3/4, 75%) and large junctional nests were detected only in PG naevi (n=1/4, 25%; p=0.0059). 
There was largely an absence of architectural disorder and cytological atypia in globular (n=8/8, 
100%) and PG naevi (n=3/4, 75%), but this was present in reticular naevi (n=3/5, 60%; p=0.0459). 
The globular, reticular and PG naevi were donated by participants with a mean age of 56.5 years 
(range 35-66 years), 50 years (range 28-65 years) and 27.75 years (range 26-33 years) respectively. 
Based upon droplet digital™ PCR (ddPCR) (see Chapter 3), the naevi subjected to cell culture were 
BRAF V600E (c.1799T>A) (n=13/17), BRAF V600E (c. 1799_1800delTGinsAA) (n=2/17), BRAF 
V600K (n=1/17) and NRAS (n=1/17) mutant. Both globular and PG naevi harboured BRAF V600E 
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(c.1799T>A) (n=7/8 and n=3/4 respectively) and BRAF V600E (c. 1799_1800delTGinsAA) (n=1/8 
and n=1/4 respectively), whereas reticular naevi harboured BRAF V600E (c.1799T>A) (n=3/5), 
BRAF V600K (n=1/5) and NRAS (n=1/5).  
Due to the difficulties associated with cell culturing, 6/17 naevi and 10/17 adjacent non-lesional 
skin cells had propagated in culture and subsequently frozen down (Table 7). None of the globular 
naevi (n=8) propagated in culture, in contrast to 80% (n=4/5) of reticular and 50% (n=2/4) of PG 
naevi. Two of the successfully cultured reticular naevi belonged to two participants whose globular 
naevi did not grow in culture (158RP and 510AN). The successfully cultured naevi were 
predominantly compound naevi on histopathology (n=5/6), had lentiginous growth and small nests 
(n=5/6) and without any architectural disorder and cytological atypia (n=4/6). The propagation of 
cells in culture was significantly associated with dermoscopic subtype (p=0.0318) and nest 
formation of junctional melanocytes (p=0.0330) (Table 9). Histopathologic subtype (p=0.0936), 
microanatomical growth pattern (p=0.1625) and architectural disorder and cytological atypia 
(p=0.5840) were not significantly associated with the propagation of cells in culture (Table 9). The 
unsuccessfully cultured globular naevi (n=8) had high naevus cellularity ranging from 50% to 80% 
naevus cell density on histopathology (Table 7). These globular naevi had a BRAF V600E fractional 
abundance (FA)16 that ranged between 19.7% and 33% (see Chapter 3 Table 3). The BRAF 
V600E/K FA in the successfully cultured reticular naevi (n=4) based upon ddPCR was 1.55% to 
12.2%, whereas the PG naevi that grew in culture (n=2) had a BRAF V600E FA of 12.4% and 
21.6% respectively; reflective of the higher naevus cellularity in the PG naevi. Notably, the 
successfully cultured reticular naevi (n=4) had a much lower naevus cellularity ranging from <5% 
to 10% (Table 7).  
In sum, the successfully cultured naevi were BRAF V600E (c.1799T>A) (n=5/6) or BRAF V600K 
(n=1/6) mutant reticular and PG naevi with mainly lentiginous growth and small nests (n=5/6) 
(Figure 12). The only reticular naevus that did not grow in culture was an NRAS mutant junctional 
naevus with lentiginous growth and small nests that had a relatively lower naevus cellularity (<1%) 
as compared to the other reticular naevi (Figure 13). The PG naevi that did not propagate in culture 
(n=2) had a lower BRAF V600E FA (6.9%) than the successfully cultured PG naevi or harboured 
the BRAF V600E (c. 1799_1800delTGinsAA) mutation detected through Sanger sequencing (FA 
not assessable).  
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Table 8. Summary of the histopathologic characteristics of the 17 sampled globular, reticular and peripheral rim of globules dermoscopic 
naevus subtypes subjected to cell culture. The indicated p-value represents a χ2 test. 
 Total Naevi Globular Reticular Peripheral Rim of Globules p-value 
Number of naevi 17 8 5 4  
Histopathologic Subtype   
Junctional 3 (18) 0 (0) 2 (40) 1 (25) 0.0074 
Compound 7 (41) 1 (12) 3 (60) 3 (75) 
Intradermal 7 (41) 7 (88) 0 (0) 0 (0) 
Microanatomical Growth Pattern   
Predominantly or entirely epidermal 5 (29) 0 (0) 3 (60) 2 (50) 0.0071 
Equivalent epidermal and dermal components 3 (18) 0 (0) 2 (40) 1 (25) 
Predominantly or entirely dermal 9 (53) 8 (100) 0 (0) 1 (25) 
Nest Formation of Junctional Melanocytes   
Absence of junctional melanocytes 7 (41) 7 (88) 0 (0) 0 (0) 0.0059 
Lentiginous growth pattern with absence of 
nests 
2 (12) 1 (12) 1 (20) 0 (0) 
Combination of lentiginous growth and small 
nests 
7 (41) 0 (0) 4 (80) 3 (75) 
Predominantly large junctional nests 1 (6) 0 (0) 0 (0) 1 (25) 
Architectural Disorder and Cytological Atypia   
Absent 13 (77) 8 (100) 2 (40) 3 (75) 0.0459 
Present 4 (23) 0 (0) 3 (60) 1 (25) 
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Table 9. Summary of the histopathologic characteristics of the 17 sampled globular, reticular and peripheral rim of globules dermoscopic 
naevus subtypes that grew and did not grow in cell culture experiments. The indicated p-value represents a Fisher’s exact test for architectural 
disorder and cytological atypia and a χ2 test for trend for the other characteristics. 
Outcome of Cell Culture Experiments Propagated (%) Did Not Propagate (%) p-value 
Total naevi (n=17) 6 (35) 11 (65)  
Dermoscopic Subtype  
Globular (n=8) 0 (0) 8 (100) 0.0318 
Reticular (n=5) 4 (80) 1 (20) 
Peripheral rim of globules (n=4) 2 (50) 2 (50) 
Histopathologic Subtype   
Junctional (n=3) 1 (33) 2 (67) 0.0936 
Compound (n=7) 5 (71) 2 (29) 
Intradermal (n=7) 0 (0) 7 (100) 
Microanatomical Growth Pattern   
Predominantly or entirely epidermal (n=5) 2 (40) 3 (60) 0.1625 
Equivalent epidermal and dermal components (n=3) 3 (100) 0 (0) 
Predominantly or entirely dermal (n=9) 1 (13) 8 (89) 
Nest Formation of Junctional Melanocytes   
Absence of junctional melanocytes (n=7) 0 (0) 7 (100) 0.0330 
Lentiginous growth pattern with absence of nests (n=2) 1 (50) 1 (50) 
Combination of lentiginous growth and small nests (n=7) 5 (71) 2 (29) 
Predominantly large junctional nests (n=1) 0 (0) 1 (100) 
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Architectural Disorder and Cytological Atypia   
Absent (n=13) 4 (31) 9 (69) 0.5840 
Present (n=4) 2 (50) 2 (50) 
 104 
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Figure 12. Dermoscopic and histopathologic features of naevi that propagated in culture. 
(First row) A 6 x 4 mm BRAF V600E mutant (FA 1.55%) reticular naevus with lentiginous 
growth and small nests and <5% naevus cellularity (158RP naevus 78). (Second row) A 9 x 5 
mm BRAF V600K mutant (FA 3.23%) reticular naevus with lentiginous growth without nests 
and <5% naevus cellularity (510AN naevus 23). (Third row) A 8 x 5 mm BRAF V600E mutant 
(FA 5.5%) reticular naevus with lentiginous growth and small nests and 10% naevus cellularity 
(1346KJ naevus 7). (Fourth row) A 8 x 10 mm BRAF V600E mutant (FA 12.2%) reticular 
compound naevus with lentiginous growth and small nests and 10% naevus cellularity (695MB 
naevus 59). (Fifth row) A 12 x 9 mm BRAF V600E mutant (FA 21.6%) PG naevus with 
lentiginous growth and small nests and 30% naevus cellularity (822MT naevus 10). (Sixth row) 
A 2 x 3 mm BRAF V600E mutant (FA 12.4%) PG naevus with lentiginous growth and small 
nests and 10% naevus cellularity (1030NW naevus 28). Of note this naevus did not meet the 
criteria for WES. 
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Figure 13. Representative dermoscopic and histopathologic features of naevi that did not 
propagate in culture. (Top row) A 8 x 6 mm BRAF V600E mutant (FA 27.1%) globular dermal 
naevus with 70% naevus cellularity (111CM naevus 3). None of the globular naevi (n=8) were 
cultured successfully. (Middle row) A 3 x 3 mm NRAS mutant reticular naevus with lentiginous 
growth and small nests and <1% naevus cellularity (903JA naevus 33). Of note, the successfully 
cultured reticular naevi (n=4/5) were BRAF V600E/K mutant. (Bottom row) A 4 x 2 mm BRAF 
V600E (c. 1799_1800delTGinsAA) mutant PG naevus with large junctional nests and 5% 
naevus cellularity (1030NW naevus 54).  
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5.4.2 BRAF mutant frequency in tissue and cultured cells 
The DNA extracted from 5/6 matched cultured naevocytes and adjacent non-lesional skin cells met 
the criteria for WES (Table 7). These were derived from BRAF V600E (c.1799T>A) (3 reticular 
and 1 PG) or BRAF V600K mutant naevi (1 PG). There was an approximately 3 to 4 fold higher 
BRAF V600E (c.1799T>A) mutant frequency in the cultured naevocytes as compared to naevus 
tissue in 2/5 paired naevi upon WES (40% vs 11% and 47% vs 15% respectively) (Table 10). This 
observed BRAF V600E mutant frequency in the cultured naevocytes and naevus tissue belonging to 
695MB was also evident via Sanger sequencing (Figure 14). Furthermore, Sanger sequencing 
performed on matched specimens (naevus tissue, adjacent non-lesional skin tissue, corresponding 
cultured cells, saliva) belonging to 695MB verified a somatic BRAF V600E mutation in the naevus 
tissue and corresponding cultured naevocytes; whereas the adjacent non-lesional skin tissue, 
adjacent non-lesional skin cultured cells and saliva were BRAF wild-type (Figure 15). The BRAF 
V600E mutation was present in naevus tissue but absent in cultured naevocytes in the other 2/5 
naevi (both reticular), whereas the BRAF V600K mutant reticular naevus had the same frequency of 
3% in naevus tissue and cultured naevocytes (Table 8). 
5.4.3 Somatic mutation count in tissue and cultured cells 
The mean somatic mutation count in cultured naevocytes is 1254 (range 654-2232), whereas the 
mean somatic mutation count shared by both naevus tissue and cultured naevocytes is 335 (range 
172-511). Hence, the mean somatic mutation count present in cultured naevocytes but absent in 
naevus tissue is 919 (range 435-2060). Therefore the vast majority of somatic mutations found in 
cultured naevocytes are absent in naevus tissue (range 55.64%-92.29%) (Table 10). It is important 
to note that the naevi with higher BRAF V600E mutant frequency in the cultured naevocytes as 
compared to naevus tissue (n=2/5) shared a higher proportion of somatic mutations between their 
corresponding naevus tissue and cultured naevocytes (Table 10). 
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Table 10. Somatic mutation count and BRAF mutant frequency (based upon WES) in naevi that grew in culture. 
*High proportion of somatic mutation count in cultured naevocytes that is absent in naevus tissue suggests that naevi are not clonal population 
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158RP 78 3012 780 2232 
(3012-780) 
172 2060 
(2232-172) 
5 0 - - 
25.90% 74.10% 7.71% *92.29% 
510AN 23 3469 2183 1286 
(3469-2183) 
378 908 
(1286-378) 
- - 3 3 
62.93% 37.07% 29.39% *70.61% 
1346KJ 7 2041 1387 654 
(2041-1387) 
219 435 
(654-219) 
14 0 - - 
67.96% 32.04% 33.49% *66.51% 
695MB 59 3108 1956 1152 
(3108-1956) 
511 641 
(1152-511) 
11 
 
40 - - 
62.93% 37.07% 44.36% *55.64% 
Pe
ri
ph
er
al
 
R
im
 o
f 
G
lo
bu
le
s 822MT 10  
2131 1186 945 
(2131-1186) 
396 549 
(945-396) 
15 47 - - 
55.65% 44.35% 41.90% *58.10% 
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Figure 14. Comparison of the BRAF mutant frequency in naevus tissue and cultured           
naevocytes belonging to 695MB via Sanger sequencing and WES.  
	 110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. BRAF mutation detection in matched specimens belonging to 695MB via Sanger 
sequencing. 
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5.5 DISCUSSION 
Reticular naevi and PG naevi were observed to propagate in culture, in contrast to globular naevi 
which did not grow in culture. The propagation of cells in culture was significantly associated with 
dermoscopic subtype and nest formation of junctional melanocytes. The BRAF mutant frequency in 
the successfully cultured naevocytes was present at a higher frequency as compared to matched 
naevus tissue in 2/5 matched specimens. In 3/5 matched naevus tissue and cultured naevocytes, 
BRAF V600K was present at the same low frequency or BRAF V600E was present in the naevus 
tissue but absent in the cultured naevocytes. Furthermore the majority of somatic mutations 
detected in the cultured naevocytes were absent in naevus tissue in all successfully cultured and 
sequenced naevi. This is the first study to compare and contrast the genotype of different 
dermoscopic naevus subtypes and their histopathologic features through characterization of cultured 
naevocytes.  
In 2013, Yeh et al2 concluded that all naevi are clonal cell populations based on ddPCR and 
immunohistochemistry (BRAF V600E-specific antibody VE1) to evaluate the BRAF V600E 
distribution within naevocytes manually microdissected from formalin-fixed paraffin-embedded 
histopathologically compound and intradermal acquired naevi. The enumeration based upon ddPCR 
of BRAF V600E mutant versus wild-type alleles of VE1 positive naevi (n=8/10) revealed that the 
number of BRAF V600E mutant alleles equaled the number of wild-type alleles, whilst the 
corrected allelic ratio of BRAF V600E to wild-type BRAF based on immunohistochemistry had an 
average ratio of 1.01 (range 0.84 to 1.12). Contrary to this theory, Lin et al3 suggested that naevi 
can be polyclonal based on their observation in single cells isolated from intradermal naevi 
(n=11/13) as well as junctional or compound acral naevi (n=2/13) using electromagnetic separation 
and laser-capture microdissection followed by polymerase chain reaction (PCR) and Sanger 
sequencing to determine the BRAF mutations. All examined naevi (n=13/13) had a combination of 
cells which were wild-type BRAF and heterozygous for BRAF V600E. A statistically significant 
number of wild-type BRAF naevocytes predominated in the majority of naevi (n=9/13). 
Furthermore a concurrent experiment by the same authors3 revealed homozygosity for BRAF 
V600E but heterozygosity of the adjacent single nucleotide polymorphism (SNP) in four 
intradermal naevi, thus indicating that the BRAF V600E mutation in these naevi originated from 
different cells.  
The assessment of ‘clonality’ of freshly acquired naevi specimens from different dermoscopic 
subgroups based on culture experiments herein reveal that globular naevi with a predominantly 
dermal growth pattern may have failed to propagate due to the high naevus cellularity and BRAF 
V600E FA, hence a higher proportion of naevus cells that harbour a fully clonal heterozygous 
BRAF mutation causing oncogene-induced senescence17. And even though the globular naevi were 
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transduced with the CDK4-R24C mutation, this was not sufficient to overcome the senescence 
block. However, optimised culture conditions for melanoblasts using both Dispase II and 
Collagenase IV may have yielded better results6. It is possible that the reticular and PG naevi grew 
in culture because the BRAF V600E/K mutation was low and not as high as seen in globular naevi. 
The 3 to 4 fold higher BRAF V600E mutant frequency in the cultured naevocytes as compared to 
naevus tissue in two successfully cultured reticular/PG naevi suggest that the culturing of these 
naevi allowed for expansion of the naevocytes, implying that naevi are clonal cell populations. 
However in seeing that there was absence of the BRAF V600E mutation in cultured naevocytes 
derived from BRAF V600E mutant naevi, and moreover the majority of somatic mutations detected 
in the cultured naevocytes were absent in naevus tissue, the alternative argument is that reticular/PG 
naevi typically characterised by presence of melanocytes at the dermoepidermal junction have 
polyclonal cell populations. Polyclonal BRAF mutations in reticular/PG naevi was in fact detected 
via the ultradeep pyrosequencing method by Zalaudek et al1 when assessing BRAF mutation 
prevalence in different dermoscopic naevi subtypes. Although the more ‘clonal’ subset of 
reticular/PG naevi herein did share a higher proportion of somatic mutations between their 
corresponding naevus tissue and cultured naevocytes, the majority of somatic mutations detected in 
the cultured naevocytes were still absent in naevus tissue. Given that a different portion of the 
naevus was subjected to culture as compared to the naevus tissue that was sequenced, this concept 
of polyclonal cell populations would help to explain the intratumoral heterogeneity observed in 
these successfully cultured reticular and PG naevi. Lin et al2 also demonstrated polyclonality in 
intradermal naevi (with the same growth pattern demonstrated by the globular naevi herein 
subjected to cell culture), albeit the present study was not able to assess for this due to failure of 
globular naevi to propagate in culture. Participant age is unlikely to be the reason why globular 
naevi did not to grow in culture as the very same participants had donated reticular naevi that were 
cultured successfully.  
The malignant transformation of a naevus is rare as approximately 70% of melanomas arise de novo 
whereas 30% (range 4-72%) of melanomas develop within a pre-existing naevus18. It has been 
proposed that intra-individual comparative analysis of naevi and dermoscopic diversity of each 
patient would allow an individual reference system to identify “the ugly duckling” - suspicious 
lesions worthy of further attention19. The diameter of a naevus also has prognostic significance, 
with malignant transformation more likely in those larger than 5mm20, possibly mediated via 
increased telomere length21 or an inherent ability to overcome senescence22. Although majority of 
the naevi subjected to cell culture herein (n=13/17) were larger than 5mm in diameter (n=7/8 
globular, n=4/5 reticular, n=2/4 PG naevi), all analysed naevi herein were in a benign state, 
supported by the absence of TERT promoter mutations that has been reported as early events in 
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malignant transformation23. Thus it would not be possible to implicate the findings of the naevi 
subjected to the culture experiments herein with clonality and risk of malignant transformation.  
It is possible that the observed genotypic difference between naevus tissue and cultured naevocytes 
herein is due to the presence of other cell types within the sequenced tissue and contamination of 
the final culture by adjacent non-lesional skin naevocytes. The culturing method used does 
inadvertently include non-naevus melanocytes that are present in the tissue and it may be possible 
that these non-naevus melanocytes can outgrow the naevocytes over time. It cannot be ascertained 
what contribution these melanocytes have in the final culture. It is unlikely that the lentiviral 
transduction of CDK4-R24C incorporated into the cell culture process to enhance the mutated allele 
and allow the mutant cells to have a selective growth advantage over wild-type cells was inefficient 
to cause the wild-type naevocytes to propagate in culture to yield this observation instead. Next-
generation sequencing artefacts may also occur. The limitations of this study is the small sample 
size and the cells that were genotyped may not be a pure population of cells given that these cells 
could not be targeted or microdissected.  
5.6 CONCLUSION 
In conclusion, the propagation of cells in culture was significantly associated with dermoscopic 
naevus subtype and nest formation of junctional melanocytes. Globular naevi did not propagate in 
culture experiments. This is postulated to be due to a higher BRAF V600E FA causing oncogene-
induced senescence. Reticular naevi and PG naevi grew in culture, possibly due to the lower BRAF 
V600E/K mutation in these dermoscopic naevi subtypes. There was a discrepancy in the BRAF 
V600E mutation prevalence between naevus tissue and cultured naevocytes and a high proportion 
of somatic mutations in cultured naevocytes were absent in naevus tissue. The intratumoral 
heterogeneity in reticular and PG naevi provides evidence for the presence of polyclonal cell 
populations in these naevi subtypes, although optimised cell culture conditions may help to yield 
better results in the culturing of globular naevi and facilitate comparisons with reticular and PG 
naevi. Future research including single-cell RNA-seq technology (e.g. chromium single cell 3’ 
solution) will assist in revealing cellular heterogeneity whereas functional work will help to 
determine the precise mechanisms that underpin the role of BRAF and other genes in initiating, 
maintaining and in the malignant transformation of naevi. 
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CHAPTER 6 
Conclusion 
The development and maintenance of naevi is comprised of a complex interplay of genomic factors 
that not only keeps naevi in a state of equilibrium but also influences their evolution and life cycle 
(Figure 16)1. The 100% mutually exclusive BRAF and NRAS mutation prevalence is in keeping with 
the hypothesis that BRAF is acquired early in naevogenesis2-4 and support the role of the mitogen-
activated protein kinase (MAPK) pathway in the development of naevi, although additional 
initiating events are most likely involved in NRAS mutant naevi. Other driver genes were also 
detected at a lower prevalence; including well-known genes (e.g. MET and GRIN2A) and novel 
genes (e.g. HDAC9, MYH11, and DCC). These novel ‘driver’ mutations were present at a similar 
mutation frequency to BRAF V600E and BRAF V600K, implying that they most likely occurred at 
the same time as BRAF during naevus formation. Given that BRAF V600 mutations are the most 
prevalent, BRAF V600 are likely to be the initiator in BRAF mutant naevi and the other genes 
contain private deleterious mutations that provide a permissive environment for naevus 
development. Ultraviolet radiation (UVR)-related mutation signature was the dominant mutation 
signature in 97% of naevi, in contrast to 100% age-related mutation signature prevalence and 
frequently observed defective DNA repair signatures in adjacent non-lesional skin, despite being 
exposed to the same degree of sunlight. This suggests that in most cases, acquired naevi occur 
following cumulative exposure to UVR together with defective DNA repair mechanisms in normal 
skin melanocytes.  
The somatic mutation landscape of globular, reticular and peripheral rim of globules (PG) naevi are 
characterised by differences in BRAF and NRAS prevalence and somatic mutation burden. 
Differences in the mutation frequency suggest that specific mutation types may contribute to the 
development of distinct dermoscopic and histopathologic naevus phenotypes. However, it is also 
important to consider other factors such as the individual’s age at naevus onset may account for the 
somatic mutation differences seen between dermoscopic patterns since there are significant age-
related differences in the onset of globular (childhood), reticular (puberty and adulthood) and PG 
naevi (puberty or early adolescence)4. This however is not possible to accurately determine without 
longitudinal monitoring. Globular naevi was 92% BRAF V600E/K mutant, associated with a higher 
somatic mutation burden that culminated in a greater proportion of UVR-related mutation signature 
but are largely genomically silent containing only minor copy number aberrations (CNAs). 
Reticular naevi were 67% BRAF V600E/K mutant and 33% NRAS mutant, whereas PG naevi were 
100% BRAF V600E mutant. The 100% BRAF V600E prevalence in PG naevi supports the notion 
that BRAF-mutant clones contribute to the growth of naevi4,5. Reticular and PG naevi shared a 
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significantly higher proportion of indels and large regional genome-wide CNAs, involving 
combined loss of melanoma-related tumour suppressor genes and oncogenes. It should be noted that 
reticular and globular naevi had similar total somatic mutation burdens and PG naevi had a many-
fold lower mutation burden. This lower mutation burden may reflect the age of onset of the PG 
naevi. This data reveals that copy number aberration (CNA) events that are absent or balanced in 
clonally expanded melanocytes contribute to the stability of naevi. The stability of naevi can also be 
attributed to the common BRAF V600E mutations that drive the initial proliferative burst which 
then initiate oncogene-induced senescence (OIS)6. Furthermore, the differences in CNAs may play 
a role in the stable life cycle and lifelong persistence of globular naevi7; and in influencing the more 
dynamic life cycle of reticular and PG naevi that subsequently leads to involution7. In contrast, 
imbalanced CNA events in a given clonal expansion of melanocytes contribute to the formation of 
early melanomas (Figure 8 in the published version of Chapter 48 – Appendix B). Lastly, the 
clinically benign state of all analysed naevi is supported by the absence of TERT promoter 
mutations, as this mutation has been reported as early events in malignant transformation9. 
The differences between globular, reticular and PG naevi was also evident in cell culture 
experiments as the propagation of cells in culture was significantly associated with dermoscopic 
naevus subtype and nest formation of junctional melanocytes. Globular naevi did not propagate in 
culture experiments possibly due to a higher BRAF V600E fractional abundance causing OIS6. In 
the successfully cultured reticular and PG naevi, a high proportion of somatic mutations detected in 
cultured naevocytes were absent in naevus tissue. The intratumoral heterogeneity provides evidence 
for the presence of polyclonal cell populations in naevi. This notion is also supported by the 
presence of concurrent NRAS mutations in NRAS mutant naevi10. 
Overall, the data generated in this study supports the role of the MAPK pathway and confirms that 
UVR strongly contributes to naevogenesis. Copy number changes reflect at a genomic level, the 
dermoscopic pattern differences of acquired naevi. The balanced loss of tumour suppressor genes 
and oncogenes is a protective mechanism of acquired naevi. The limitations include a small sample 
size as the naevi are also subcategorised into dermoscopic patterns. Should there be more time and 
an unlimited budget, exome sequencing on a larger sample size of the dermoscopic naevi subtypes 
would provide more evidence for thesis Aim 1 (ascertain if there are common somatic mutations or 
pathway activation driving naevogenesis in different dermoscopic naevus subtypes) Optimised cell 
culture conditions would help to yield better results in the culturing of globular naevi and facilitate 
comparisons with reticular and PG naevi for thesis Aim 3 (compare and contrast the genotype of 
different dermoscopic naevus subtypes with histopathologic features through characterisation of 
cultured naevocytes).  
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Other limitations of this study is that it is focused on analysing somatic mutations confined to naevi 
of interest, even though melanoma risk can also be influenced by other phenotypic characteristics 
such as naevus counts and clinically atypical naevi, together with gene expression dysregulation. 
We assessed all coding exons plus the untranslated regions (UTRs), however noncoding variants 
contained in introns and intergenic regions will be missed. Further studies will be needed to 
investigate if these variations have a role in naevogenesis and malignant transformation. The scope 
of this study also does not include analysis of the expression profiles from the genetic mutations 
that may be identified. Nonetheless, comparing the naevi genotype and phenotype with a pure 
population of cultured melanocytes will provide a source of validation for the findings in this study 
to be extended to future functional studies.  
This study has contributed to the clinico-dermoscopic-pathologic-genomic correlation of acquired 
naevi with the globular, reticular and peripheral rim of globules dermoscopic patterns1 that 
correspond to different microanatomical growth patterns2,11,12 and are distinguished by their time of 
onset3,4, life cycle4 and relative melanoma risks3,4,12. The findings in this thesis have provided 
insight into naevogenesis and distinguished some of the molecular hallmarks of naevi in relation to 
melanoma8,10. Future studies on signalling pathways via transcriptome analysis and protein studies 
would help to elucidate the clinical significance of the somatically acquired mutations in 
melanocytic naevi and adjacent non-lesional skin. Protein studies would also unveil the outcome of 
gene expression on protein function in contributing to naevus phenotype and behaviour. These 
future studies would hopefully shed more light on the mechanisms of naevogenesis, maintenance of 
naevi in a state of equilibrium and naevi involution, in order to better understand melanomagenesis. 
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Figure 16. The clinico-pathologic-genomic correlation of globular, reticular and peripheral 
rim of globules subtypes of acquired naevi1. A summary of the common clinical presentation 
of globular, reticular and peripheral rim of globules subtypes of acquired naevi and the 
corresponding histopathology. The common BRAF and NRAS mutation prevalence, total 
mutations per megabase and indels differ across the dermoscopic naevi subtypes. In all 
dermoscopic subtypes, somatic mutation prevalence are commonly found in order of age, 
ultraviolet radiation (UVR) and defective DNA repair prevalence. Genome-wide copy number 
aberrations (CNAs) are largely absent in globular naevi, whereas reticular naevi and naevi with a 
peripheral rim of globules have numerous CNAs which are balanced events, with loss of tumour 
suppressor genes and oncogenes. 
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